US20230024683A1 - Implantable intraocular pressure sensors and methods of use - Google Patents
Implantable intraocular pressure sensors and methods of use Download PDFInfo
- Publication number
- US20230024683A1 US20230024683A1 US17/937,062 US202217937062A US2023024683A1 US 20230024683 A1 US20230024683 A1 US 20230024683A1 US 202217937062 A US202217937062 A US 202217937062A US 2023024683 A1 US2023024683 A1 US 2023024683A1
- Authority
- US
- United States
- Prior art keywords
- implant
- pressure sensor
- pressure
- assembly
- sensor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/16—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for measuring intraocular pressure, e.g. tonometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0031—Implanted circuitry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6861—Capsules, e.g. for swallowing or implanting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0064—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/18—Use of ingredients of undetermined constitution or reaction products thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Physiology (AREA)
- Prostheses (AREA)
- Eye Examination Apparatus (AREA)
Abstract
Intraocular pressure sensors, systems, and methods of use. Implantable intraocular pressure sensing devices that are hermetically sealed and adapted to wirelessly communicate with an external device. The implantable devices can include a hermetically sealed housing, the hermetically sealed housing including therein: an antenna in electrical communication with a rechargeable power source, the rechargeable power source in electrical communication with an ASIC, and the ASIC in electrical communication with a pressure sensor.
Description
- This application is a continuation of, and claims priority under 35 U.S.C. 120 to, U.S. application Ser. No. 16/302,750, filed on Nov. 19, 2018, which is a national-phase application, under 35 U.S.C. 371, of International Application No. PCT/US2017/035247, filed on May 31, 2017, which in turn claims priority to U.S. Provisional Application No. 62/343,593, filed May 31, 2016, the disclosure of which is incorporated by reference herein.
- This disclosure incorporates the following publications by reference herein: U.S.
- 8,475,374; U.S. Pat. No. 9,078,613; US 2010/0137694; US 2010/0179449; and US 2014/0296687.
- All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- Glaucoma is second only to cataract as a leading cause of global blindness and is the leading cause of irreversible visual loss. Worldwide, there were 60.5 million people with open angle glaucoma and angle closure glaucoma in 2010, projected to increase to 79.6 million by 2020, and of these, 74% will have OAG. (Quigley and Broman, in Br J Ophthalmol. 2006; 90(3), pp 262-267). Of those with ACG, it is predicted that 70% will be women and 87% will be Asian. Open-angle glaucoma affects more than 2 million individuals in the United States. Owing to the rapid aging of the US population, this number will increase to more than 3 million by 2020, and approximately a total of 4 million glaucoma cases. Bilateral blindness from glaucoma is projected to affect greater than 11 million by 2020 globally. Risk factors for open-angle glaucoma include increased age, African ethnicity, family history, increased intraocular pressure, myopia, and decreased corneal thickness. Risk factors for angle closure glaucoma include Inuit and Asian ethnicity, hyperopia, female sex, shallow anterior chamber, short axial length, small corneal diameter, steep corneal curvature, shallow limbal chamber depth, and thick, relatively anteriorly positioned lens.
- Elevated intraocular pressure (“TOP”) is the most important known risk factor for the development of POAG, and its reduction remains the only clearly proven treatment. Several studies have confirmed that reduction of IOP at any point along the spectrum of disease severity reduces progression (Early Manifest Glaucoma Treatment Trial to Advanced Glaucoma Intervention Study). Also, IOP reduction reduces the development of POAG in patients with ocular hypertension (OHT) and reduces progression in patients with glaucoma despite normal IOP, as seen in the Collaborative Normal Tension Glaucoma Study. The normal IOP for 95% of Caucasians is within the range of 10-21 mm Hg. While increased IOP is a strong risk factor for the development of glaucoma, it must be remembered that many people with glaucoma have untreated IOPs of 21 mm Hg or less. In general, it is estimated that approximately 50% of POAG is of the normal tension variety. However, studies have found a wide range in the prevalence of normal tension glaucoma among individuals with OAG. For example, normal tension glaucoma was diagnosed in 1/3 of the OAG patients in the Barbados Eye Studies, and 85% of the individuals with OAG in a Chinese population. At this time, the risk associated with long-term fluctuation of TOP over months to years remains controversial. The EGPS and Early Manifest Glaucoma Treatment Trial found that long-term TOP fluctuations were not associated with progression of glaucoma, while the AGIS study found an increased risk of glaucoma progression with increased long-term TOP fluctuation, especially in patients with low TOP.
- Currently, TOP reduction remains the only treatment option for glaucoma, with options depending on many factors such as the type of glaucoma. Current monitoring of TOP occurs in the offices of a vision care practitioner, typically an ophthalmologist, ranging from once a year to once every 3-6 months, once glaucoma is diagnosed. It is known that TOP varies over a wide range in individuals, including a diurnal fluctuation, longer term variations and occurrence of spikes in TOP, therefore a single measurement cannot provide adequate data to diagnose an elevated TOP, requiring prescription of pressure regulating or pressure reducing medication. Treatment options for reduction of TOP include medical therapy, such as beta blockers, alpha agonists, miotics, carbonic anhydrase inhibitors, and prostaglandin analogues, administered as eyedrops, up to 4 times a day; laser treatment, such as argon laser trabeculoplasty (ALT), selective laser trabeculoplasty (SLT), neodymium-doped yttrium aluminum garnet (Nd:YAG) laser iridotomy, diode laser cycloablation, and laser iridoplasty; surgical procedures including iris procedures (e.g., peripheral iridectomy), angle procedures (e.g., goniotomy and trabeculotomy), filtration procedures (e.g., trabeculectomy) and non-penetrating filtration procedures (e.g., deep sclerectomy and viscocanalostomy); and drainage shunts including episcleral implants (e.g., Molteno, Baerveldt, and Ahmed) or mini-shunts (e.g., ExPress Mini Shunt and iStent).
- Prevalence of glaucoma in white (A) and black and Hispanic (B) subjects is shown in BES, Baltimore Eye Survey, Baltimore, Md.; BDES, Beaver Dam Eye Study, Beaver Dam, WI; BMES, Blue Mountain Eye Study, Sydney, NSW; Melbourne VIP, Melbourne Visual Impairment Project, Melbourne, VIC; RS, Rotterdam Study, Rotterdam, the Netherlands; Barbados, Barbados Eye Study, Barbados, West Indies; KEP, Kongwa Eye Project, Tanzania; and Proyecto VER, Vision Evaluation Research, Nogales and Tucson, Ariz. “Eye Diseases Prevalence Research Group (2004) Prevalence of open-angle glaucoma among adults in the United States.”, Arch Ophthalmol 122:532-538.
- A substantial majority of glaucoma patients are treated by medication to control TOP, sometimes over three decades. Patients treated surgically or using laser treatment may also be administered medication. Lack of compliance of patients to long term medication protocols is exacerbated by advancing age and lack of positive concrete immediate incentives.
- Monitoring compliance -continuous monitoring of TOP replaces the standard practice of monitoring TOP episodically, hence provides a more accurate and detailed account of patient compliance, enabling the caregiver to take steps to take additional steps to enhance compliance if required.
- Monitoring efficacy of prescribed treatment -continuous TOP data following a change in treatment modality or protocol provides the caregiver with a prompt feedback on the efficacy of the change in treatment and thereby supports a better outcome.
- Post market monitoring of approved glaucoma treatments -newly approved glaucoma treatments may require post market monitoring by health care agencies in order to monitor safety and efficacy on the targeted patient population Data from continuous monitoring of TOP may be submitted by manufacturers of newly approved drugs or devices to meet this requirement.
- Clinical research on efficacy of novel glaucoma treatments -data recorded may be used by clinical researchers to monitor efficacy and may be submitted to regulatory authorities for prompt approval, if the results so warrant.
- The references below describe some earlier concepts related to monitoring intraocular pressure.
- 1. “An implantable microfluidic device for self-monitoring of intraocular pressure”, by Mandel, Quake, Su and Araci, in Nature Medicine 20, 1074-1078 (2014). Three images of a microfluidic intraocular sensor are shown in this reference. The sensor comprises a 50×50 μm2 cross-section channel connected to the eye fluid on one side and to a 0.5 mm×2.0 mm×0.3 mm volume reservoir (Vreservoir) on the other.
- 2. “Implantable parylene-based wireless intraocular pressure sensor”, by Chen, Rodger, Saati, Humayun and Tai in IEEE 21st International Conference on Micro Electro Mechanical Systems, 2008. MEMS 2008. This paper presents an implantable, wireless, passive pressure sensor for ophthalmic applications. Two sensor designs incorporating surface-micro-machined variable capacitor and variable capacitor/inductor are implemented to realize the pressure sensitive components. The sensor is monolithically micro-fabricated using parylene as a biocompatible structural material in a suitable form factor for increased ease of intraocular implantation. Pressure responses of the micro-sensor are characterized on-chip to demonstrate its high pressure sensitivity (>7000 ppm/mmHg) with mmHg level resolution. An in vivo animal study verifies the biostability of the sensor implant in the intraocular environment after more than 150 days.
- 3. “Rollable and implantable intraocular pressure sensor for the continuous adaptive management of glaucoma”, Piffaretti, Barrettino, Orsatti, Leoni, Stegmaier, in Conference Proceedings IEEE Eng Med Biol Soc, 2013; 2013:3198-201. doi: 10.1109/EMBC.2013.6610221.
- 4. “Implantable microsensor, telemetrically powered and read out by patient hand-held device”, by Implandata Ophthalmic Products GmbH Kokenstrasse 5 30159 Hannover Germany, 2014. The Eyemate® by Implandata Ophthalmic Products GmbH is also an example.
- 5. “Preliminary study on implantable inductive-type sensor for continuous monitoring of intraocular pressure”, by Kim YW, Kim MJ, Park, Jeoung, Kim SH, Jang, Lee, Kim JH, Lee, and Kang in Clinical & Experimental Ophthalmology, 43(9), pp 830-837, 2015.
- 6. “An intra-ocular pressure sensor based on a glass reflow process”, by Haque and Wise in Solid-State Sensors, Actuators, and Microsystems Workshop, Hilton Head Island, South Carolina, Jun. 6-10, 2010.
- 7. Some earlier approaches used a capacitive-based membrane pressure sensor. For example, a diaphragm can deflect under pressure, changing the effective distance between two parallel plates, and thus increasing the measured capacitance across the plates. An example is “Miniaturized implantable pressure and oxygen sensors based on polydimethylsiloxane thin films”, Koley, Liu, Nomani, Yim, Wen, Hsia: in Mater.
Sci. Eng. C 2009, 29, 685-690. - 8. “Microfabricated implantable Parylene-based wireless passive intraocular pressure sensors”, by Chen, Rodger, Saati, Humayun, Tai: J. Microelectromech. Syst. 2008, 17, 1342-1351.
- 9. “An Implantable, All-Optical Sensor for Intraocular Pressure Monitoring”, by Hastings, Deokule, Britt and Brockman in Investigative Ophthalmology & Visual Science, 2012. Vol.53, pp 5039. A simplified approach to IOP monitoring based on a near infrared (NIR) image of an implanted micromechanical sensor is presented. The sensor chip contains one or more vacuum reference cavities formed by a flexible membrane, a rigid substrate, and a thin spacer. Both substrate and membrane partially reflect light to form an interference pattern of concentric rings. These rings shift radially as the membrane deflects in response to pressure changes. IOP is measured by analyzing a narrow-band NIR image of the pattern.
- 10. “Chronically Implanted Pressure Sensors: Challenges and State of the Field”, A Review by Yu, Kim and Meng, in
Sensors 2014, 14, 20620-20644; doi:10.3390/s141120620. - 12. “Polymer-based miniature flexible capacitive pressure sensor for intraocular pressure (IOP) monitoring inside a mouse eye”, by Ha, de Vries, John, Irazoqui, and Chappell in Biomed Microdevices (2012) 14:207-215, DOI 10.1007/s10544-011-9598-3.
- 13. “Intra-ocular pressure sensor”, U.S. Pat. No. 8,475,374 B2, by Irazoqui, Chow, Chappelle, Yang, and Ziaie, 2013.
- One aspect of the disclosure is a hermetically sealed implantable intraocular pressure sensor assembly adapted to wirelessly communicate with an external device. The assembly can include a hermetically sealed housing, the hermetically sealed housing can include therein: an antenna in electrical communication with a rechargeable power source, the rechargeable power source in electrical communication with an ASIC, and the ASIC in electrical communication with a pressure sensor.
- In some embodiments, the antenna is part of a first circuit adapted to supply power to the rechargeable power source, and the antenna is also part of a second circuit adapted to transmit data to the external device.
- In some embodiments, the assembly further comprises a flexible circuit, the flexible circuit in electrical communication with the pressure sensor and the ASIC. The flexible circuit can be in electrical communication with the antenna and the power source.
- In some embodiments, the assembly further comprises a casing comprising a titanium layer. The titanium layer can be coated with an electrically insulating ceramic layer, wherein said ceramic layer has lattice constants that match those of Titanium. The titanium layer can be coated with a hydrogel coating, wherein said hydrogel layer has a gradient in cross-link density.
- The hydrogel layer can have a gradient in number density of hydroxyl groups, said gradient being in the opposite direction of the gradient in cross-link density. The hydrogel layer can be impregnated with an anticlotting agent. The hydrogel layer can be impregnated with an anti-inflammatory agent. An outer surface of the hydrogel coating can be textured to stimulate a controlled fibrotic response. The coating can be infused with at least one of an anti-inflammatory agent and an anticlotting agent. The coating can be chemically bonded to medicaments that are slowly and sustainably released into the eye over a period of not less than 10 days. The textured surface can include a plurality of depressions, each of which have a height between 5 microns and 15 microns, such as 7.5 microns and 12.5 microns, such as 10 microns.
- In some embodiments, the pressure sensor comprises a hermetically sealed module comprising an inert fluid situated inside the module. The hermetic seal encasing said pressure sensor can include a Titanium foil of thickness in the range of 5-25 microns, the foil being undulated to enhance its surface area and resistance to mechanical stress. The sensor can comprise a piezoelectric sensing element wherein said inert fluid of
claim 12 transmits hydrostatic pressure to said sensing element through said Titanium foil. The sensor can comprise a capacitative sensing element wherein said inert fluid ofclaim 12 transmits hydrostatic pressure to said sensing element through said Titanium foil. The sensor can have dimensions of length 0.2 mm to 1.5 mm in length, 0.2 mm to 0.7 mm in width and 0.1 mm to 0.7 mm in thickness. - In some embodiments, the antenna has a space filling design, wherein the antenna is connected to an electrical circuit that can be adjusted for its electrical impedance as a function of its resistive load. The antenna can be disposed on a ceramic substrate situated inside a Titanium casing, wherein said antenna assembly being of thickness in the range 100-500 microns. The circuit comprising the antenna can have a Q factor in the range of 10-50 under use conditions.
- The antenna can be comprised of vacuum deposited metal filaments on a ceramic substrate. The antenna can provide both data transfer and energy transfer functions. The antenna can comprise a conductive length of no less than 15 mm and no more than 100 millimeters. The antenna can transmit electromagnetic energy at a frequency that is not harmful to the human body.
- In some embodiments, the ASIC comprises a microelectronic circuit comprising a microcontroller, a flash memory, a non-volatile memory and a logic circuit. The logic circuit can comprise power management and data management modules. The ASIC comprises a microelectronic circuit wherein said microelectronic circuit comprises conductive connectors of width in the range 36-360 nanometers.
- In some embodiments, the implantable assembly has a length not greater than 4.8 mm (e.g., not greater than 4.5 mm), a height not greater than 1.5 mm, and a width not greater than 1.5 mm.
- In some embodiments, the pressure sensor is disposed inside of a fluid filled chamber. The fluid filled chamber can include a flexible membrane adapted to transmit pressure from the external environment to a fluid within the fluid filled chamber. The flexible membrane can be 5-20 microns thick, such as 7-17 microns thick. The flexible membrane can be selected from the group consisting of film forming materials that provide a barrier to gas diffusion, including diffusion of air and water, for example only, Titanium, Parylene, polyimides such as Kapton, polyaromatics such as polyphenylene, etc.
- In some embodiments, the pressure sensor is adapted to sense intraocular pressure more than once every 12 hours and no more than once every 10 milliseconds, and wherein the ASIC is adapted to facilitate the storage of pressure data more than once every 12 hours and no more than once every 10 milliseconds.
- In some embodiments, the assembly further comprises an external device in wireless communication with the implantable assembly. The external device can have a communication component that is adapted to transmit a wireless signal to the implantable assembly indicating its readiness to receive data from the implantable assembly and provide wireless power to the implantable assembly, and wherein the ASIC is adapted to acknowledge the transmitted wireless signal with one of at least two different signals, indicating its readiness to transmit or receive data and its readiness to receive wireless power.
- In some embodiments, the ASIC has a communication component that is adapted to transmit pressure data from the implantable assembly to the external device, wherein the external device has a communication component that is adapted to receive the transmitted pressure data, wherein the ASIC is adapted to transmit the pressure data upon receiving a trigger signal from the external device and after acknowledging the receipt of the trigger signal.
- In some embodiments, the ASIC has a communication component that is adapted to transmit pressure data from the implantable assembly to the external device, wherein the external device has a communication component that is adapted to receive the transmitted pressure data, wherein the ASIC is adapted to transmit the pressure data upon receipt of an acknowledgment signal from the external device of receipt of a trigger signal from the implantable assembly.
-
FIG. 1 schematically illustrates exemplary components of an exemplary implant. -
FIG. 2 illustrate an exemplary implant with a flexible connector portion. -
FIG. 3 illustrate an exemplary implant with a longer flexible connector portion than the exemplary implant inFIG. 2 . -
FIGS. 4A, 4B and 4C illustrates some exemplary views of an exemplary implant, which can be the same as or similar to the exemplary implantFIG. 2 . -
FIGS. 5A and 5B illustrate perspective sectional and front sectional views, respectively, of an exemplary first portion of an implant. -
FIGS. 6A and 6B show side assembled and side exploded view of the exemplary first portion of an implanted device fromFIGS. 5A and 5B . -
FIGS. 7A, 7B and 7C illustrate an exemplary sensor portion of an implant. -
FIGS. 8A, 8Bi , 8Bii, 8C, 8D and 8E illustrate an exemplary embodiment of an implant and an exemplary delivery device. -
FIGS. 9A, 9B and 9C illustrate an exemplary implant, wherein the implant is adapted such that the sensor can rotate relative to the main housing about an axis, and the rotation axis is perpendicular relative to the main implant body. -
FIGS. 9D and 9E illustrate merely exemplary antenna design and placement in any of the implants herein. -
FIGS. 10A and 10B (side and top views, respectively) illustrate an exemplary implant that is adapted such that the sensor can rotate relative to the main housing about an axis, such that is can flex up or down relative to the elongate axis of the main housing. -
FIGS. 11A and 11B (top and side views, respectively) illustrate an exemplary implant that includes a main body and a sensor. -
FIGS. 12A-12G illustrate an exemplary implant that has a general square configuration. -
FIG. 13 illustrates a portion of an exemplary implant in which a pressure sensor is hermetically sealed inside a fluid chamber. -
FIGS. 14A and 14B illustrate that some exemplary implants can be coated with a biocompatible coating that may be optionally infused with weakly bonded to an anti-inflammatory agent or an anticoagulant. -
FIG. 15 illustrates an exemplary implant that includes sensor and electronics mounted on an exemplary glaucoma draining device. -
FIG. 16 illustrates an exemplary implant and an exemplary external device, and an exemplary communication protocol between the implant and external device. -
FIG. 17 illustrates a merely exemplary schematic of operation of an exemplary autonomous intraocular pressure sensor system. -
FIG. 18 illustrates exemplary implant locations, including but not limited to the anterior and posterior chamber, below the conjunctiva, and in Schlemm's canal. -
FIGS. 19A and 19B (side and front views, respectively) illustrates the anatomy of a portion of the eye, illustrating exemplary locations for the one or more implants. -
FIGS. 20A and 20B show human (a), and rabbit eye (b) to scale. -
FIG. 21 illustrates a further exemplary schematic of operation of an exemplary autonomous intraocular pressure sensor system. - This disclosure relates generally to intraocular pressure sensors, intraocular pressure sensing, and systems for using, and the use of, the sensed pressure or information indicative of the sensed pressure. The sensors and methods herein may also, however, be used in sensing pressure in areas near or outside of the eye. For example, sensors and methods of use herein may be used in episcleral, cardiac or neural applications, including the brain.
- Some aspects of the disclosure include implantable intraocular pressure sensors that are adapted, configured, and sized to be positioned and stabilized within the eye and communicate, optionally wirelessly, with one or more devices positioned within or outside the eye. A wireless intraocular pressure sensor may be referred to herein as a “WIPS,” and an implantable device may be referred to herein an implant, or an implantable portion of a system.
- Some of the devices, systems, and methods of use herein provide an exemplary advantage that they can sense intraocular pressure more frequently than possible with traditional tonometry and office visits, and can thus provide more frequent information regarding the change in pressure of an eye. For example, some devices herein are adapted to sense intraocular pressure continuously, substantially continuously, or periodically (regular intervals or non-regular intervals) when implanted in an eye.
- An autonomous, implantable sensor is preferred in order to provide monitoring, optionally continuous, of TOP, in order to avoid relying on the patient to perform monitoring and management tasks that can be quite onerous for a sensor continuously recording TOP data. An autonomous implanted sensor can include an electrically operated sensor that measures pressure of the aqueous humor and converts it to an electrical signal, an internal power source, optionally provided by a rechargeable battery, an electrical controller such as a microcontroller or an ASIC to manage the electronic system, a memory unit comprising volatile and/or non-volatile memory, and a wireless link in order to, optionally, receive power wirelessly, download data to an external device, and optionally a data uplink to allow reprogramming capability. The data can be downloaded into a smart phone or a tablet that serves a data uplink to a caregiver's computer via a wireless or cabled network. Power can be provided from an external charging unit that has its own power management integrated circuit (PMIC), and may also have a wireless data transfer capability, and thus can function as an interface between the implanted device and the smart phone or a tablet.
-
FIGS. 1-17 and 21 illustrate aspects of merely exemplary implants that can be used with the systems and methods of use herein.FIG. 1 schematically illustrates exemplary components of anexemplary implant 10. Any of the implants herein can include a pressure sensor, a housing that hermetically surrounds an ASIC and battery, and a flexible substrate/connector to which the housing and pressure sensor are secured. The flexible substrate/connector can include an electrical connection to the pressure sensor and antenna. - One of the challenges when designing a wireless implant that includes an intraocular pressure sensor is conceiving of a way to incorporate components into a hermetically sealed device that includes a pressure sensor, antenna, power source, and controller, wherein the device can be implanted securely and safely into the eye, and still provide and communicate sensed data or information indicative of intraocular pressure to an external device.
-
Exemplary implant 10 includesfirst portion 12 secured tosensor portion 14 viaconnector portion 16.Substrate 22 extends betweensensor portion 14 andfirst portion 12.Sensor portion 14 includes at least onepressure sensor 20 disposed within anencapsulation 18, optionally silicone or other similar material.Sensor 20 is in operable pressure communication with the external environment, such that external pressures can be transmitted topressure sensor 20. This can be, for example, via an area of sensor portion 14 (e.g., encapsulation 18) that does not extend over thepressure sensor 18 as shown. -
Substrate 22 carries electronics that allow signals fromsensor 18 to be communicated tofirst portion 12. Data or signals indicative of sensed data can be communicated viasensor portion 14 tocontroller 32 with sealedvias First portion 12 includestop casing 24 andbottom casing 26, which together form a hermetic seal that houses components therein. Top and bottom casings can be, in some embodiments, rigid glass material or titanium. The first portion also includesbattery 30, and can also includewater getter 28, andfree volume 29. -
FIGS. 2 and 3 illustrate substantially thesame implants implant 60 having a longerflexible connector portion 66 thanimplant 42's connector portion 46. Both implants include afirst portion 42/62, respectively, secured to the sensor portion via the flexible connector portion. Both implants also includesensor portion 44 and 64 respectively, which includesensors First portions -
Connector portions 46 and 66 each also includebend regions 47/67, respectively. Bendregions first portions 42/62. The bend regions are optional, as other embodiments do not necessarily need to include them. - In some embodiments the implant has an overall length such that the pressure sensor can be positioned in the anterior chamber and the housing is positioned in the suprachoroidal space of an average adult. The flexible substrate can include a bend, or region of increased curvature, as shown in some embodiments herein.
-
FIGS. 4A-4C illustrates some exemplary views of the exemplary implant, which can be the same or similar asimplant 40 fromFIG. 2 , and which illustrate exemplary specific dimensions. The implants herein can be configured and sized to fit within a 0.6 mm to 2.0 mm outer diameter, and in particular a 1.0 mm outer diameter lumen, such as a needle. The dimensions shown in theFIGS. 4A-4C are illustrative and not limiting. -
Implant 80 includesfirst portion 82,sensor portion 84, andconnector portion 86. A casing orencapsulation 88 extends aroundsensor portion 84,connector portion 86, and along the bottom offirst portion 82.Sensor portion 84 includespressure sensor 90 disposed withinencapsulation 88, but encapsulation can have a window therein sosensor 90 is in pressure communication with the environment. Thefirst portion 82 can include any of the electronics and other components (battery, memory, antenna, etc.) described herein. Substrate orbase layer 92 extends from thesensor portion 84 to thefirst portion 82, and carries electronics (e.g., flex circuits printed on a substrate) that electricallycouple sensor 90 and electronics withinfirst portion 82.Substrate 92 also comprises an antenna adapted for wireless data and power transfer. - As shown in the side view of
FIG. 4A , the exemplary length of the housing offirst portion 82 is 3.3 mm, whereas the height of the housing and encapsulation is 0.81 mm. As shown in the top view ofFIG. 4B , the overall length of the implant is 6.0 mm. As shown in the front view ofFIG. 4C , the overall width is 1.0 mm, while the exemplary sensor portion (including encapsulation) is 0.9 mm wide and 1.2 mm tall. The height of the overall device 3.0 mm. -
FIG. 4A illustrate thatconnector portion 86 has abend 83 along its length closer to thesensor portion 84 thanfirst portion 82, and is flexible along its length, and the flexibility ofconnector portion 86 allows sensingportion 84 to move relative tofirst portion 82. In an at-rest, or nondeformed configuration, thebend 83 inconnector portion 86 is such thatconnector portion 86 andsensor portion 84 have axes that are orthogonal to each other.Bend 83 can have a single radius of curvature of can have a varying radius of curvature. -
Encapsulation 83 can be a deformable material such as silicone (compatible with off-the-shelf piezo and capacitive MEMS sensors). Top andbottom portions - The flexible electronics on the substrate can include the contacts for the sensor and the antenna. Incorporating an antenna into the flexible substrate is one way of incorporating an antenna into a compact implantable device while still allowing for data and power transmission.
-
FIGS. 5A and 5B illustrate perspective sectional and front sectional views, respectively, offirst portion 82.First portion 82 includes top andbottom housings hermetic seal 95. The flexible electronics onsubstrate 92 are in electrical communication withvias 104, which are electrically coupled to housing electronics such as processor 98 (which can be an ASIC) andrechargeable battery 100.Optional water getter 102 is also disposed in the top portion offirst portion 82. -
First portion 82 also includescoating 106 thereon, which can be, for example without limitation, gold. -
FIGS. 6A and 6B show side assembled and side exploded view offirst portion 82 of an implanted device fromFIGS. 5A and 5B . This first portion can be incorporated into any of the other embodiments herein. The relevant description ofFIGS. 5A and 5B can similarly apply toFIGS. 6A and 6B .FIG. 6B illustrates more clearly the assembly and the manner in which the components are electrically coupled. The housing includesmetallization 99, which provides an electrical connection with the flexible electronics on thesubstrate 92. Disposed betweentop housing 94 andbottom housing 96 isseal 95 andelectrical connections 107, which are electrically coupled tovias 104. Connects 105 are in electrical communication withbattery 100. -
FIGS. 7A, 7B and 7C illustrateexemplary sensor portion 84 fromFIGS. 4A-4C , but can be any of the sensor portions herein.FIG. 7A is a front view,FIG. 7B is a side view, andFIG. 7C is an exploded perspective front view. What can be seen is thatencapsulation 88 andsubstrate 92 both include aligned windows or apertures therein, which allows the pressure sensor to communicate with the external environment. The windows together create opening 108 (seeFIG. 12B ) in the sensor portion. The windows may be filled with a material that allows pressure to be communicated to pressure sensor. The pressure sensor is “face down” on the flexible substrate and thus able to sense pressure via the access holes shown. The sensor electrical contact pads can be directly in contact with electronics on the flexible substrate, which can remove the need for wiring/wire bonding and requires an opening in the flex substrate and an opening in the encapsulation. Conductive lines/bond pads, and optional Parylene C coatings at piezo bridges are not shown in the figures, but can be included. - In any of the delivery procedures herein, an incision made in the eye during delivery can be 1mm oval, or may be 1.2 mm.
-
FIGS. 8A-8E illustrate an exemplary embodiment ofimplant 140 and exemplary delivery device. In this exemplary embodiment, the implant does not include a flexible elongate connector portion with a bend as in some of the embodiments above. -
FIG. 8A shows a portion ofimplant 140.Sensor 142 is disposed at a first end ofimplant 140, and is coupled tohousing 144. Housing 144 can include any components of any of the first portions herein.Housing 144 includes the encapsulation that encapsulatesantenna 152, controller 150 (e.g., an ASIC),power source 146, andfeedthrough 148 that connectsASIC 150 to theantenna 152. As in other embodiments herein,implant 140 can also include a metallic coating on the glass housing for hermeticity, one or more electrical lines on one or more glass or titanium substrates, an antenna ground plane, and a water getter (inside housing). -
FIG. 8Bi and 8Bii illustrateimplant 140 fromFIG. 4A but includes abiocompatible cover 160, optionally a polymeric material, including a plurality of sensorprotective flaps 162 that extend at a first end (two are shown), amechanical stop 164 for interfacing with a delivery device for insertion, and a conicalsecond end 166 to ease the injection.Implant 140 is disposed insidecover 160, with two sides ofsensor 140 protected by theflaps 162. Top and bottom sides ofsensor 142 are not covered bycover 160. -
FIGS. 8C and 8E illustrates anexemplary delivery tool 170 adapted and configured to interface with cover 160 (withimplant 140 therein), which is shown inFIG. 8D , but inverted relative toFIGS. 8Bi .Delivery tool 170 is adapted to facilitate the implantation ofimplant 140 andcover 160.Delivery tool 170 includes amain body 172 from which extend a first plurality ofextensions 174 and a second plurality of extensions 176 (in this embodiment there are two of each).Extensions 174 are shorter thanextensions 176 and are radially outward relative toextensions 176. One of theextensions 174 is aligned with one of theextensions 176, and the other ofextensions 174 is aligned with the other ofextensions 176. The plurality ofextensions 174 interface withstops 164 ofcover 160 whencover 160 is fully advanced within theinner space 178 oftool 170. Arms orextensions 162 oncover 160 are similarly sized and configured to fit within the space defined byarms 174. The radiallyinner arms 176 are positioned just slightly radially inward, and are sized and configured to be disposed within elongate channels withincover 160, which can be seen inFIG. 8E . In thisembodiment body portion 172 oftool 170 has the same or substantially the same outer diameter as thecover 160. Theelongate arms 176 can stabilize the relative positions oftool 170 and the implant during the delivery process. -
FIGS. 9A-9C illustrate an exemplary alternative embodiment to that shown inFIGS. 8A and 8B , but in this embodiment the implant is adapted such thatsensor 170 can rotate relative to the main housing about axis “A,” and the rotation axis is perpendicular relative to the main implant body. All other components are described above and are not relabeled for clarity.FIG. 9A is a perspective view, andFIG. 9B is a top view.FIG. 9C is a top with cover, showing the two arms flexing with the rotation of the sensor. The protective cover follows the sensor orientation, as shown inFIG. 9C . In some embodiments the sensor can rotate up to 90 degrees, and in some embodiments no more than 45 degrees, such as 40 degrees or less, or 35 degrees or less, or 30 degrees or less, or 25 degrees or less, or 20 degrees or less, such as 12 degrees. In some embodiments the sensor is rotatable from 0 to about 90 degrees (e.g., 95 degrees). The implant inFIGS. 9A-C can be the same as the implant inFIGS. 8A-E in all other regards. -
FIGS. 9D and 9E illustrate merely exemplary antenna design and placement in any of the implants herein. The antennas in the implant inFIG. 9A-9C can have other configurations and sizes as well. - Exemplary lengths for the implants shown in
FIGS. 8A and 8A (without the cover) are 3-5 mm, such as 3.3 mm to 4.7 mm, such as 3.5 mm to 4.5 mm, such as 3.7 mm to 4.3 mm, such as 4 mm. Exemplary lengths for the covers herein, such ascover 160 fromFIG. 8Bi are 4 mm to 6 mm, such as 4.3 mm to 5.7 mm, such as 4.5 mm to 5.5 mm, such as 4.7 mm to 5.3 mm, such as 5 mm. Exemplary widths for the implants shown inFIGS. 8A and 8A (without the cover) are 0.5 mm to 1.5 mm, such as 0.7 mm to 1.3 mm, such as 1 mm. -
FIGS. 10A and 10B (side and top views, respectively) illustrate an alternative implant similar to that shown inFIGS. 9A-C , but in this embodiment the implant is adapted such thatsensor 180 can rotate relative to the main housing about axis “A,” such that is can flex up or down relative to the elongate axis of the main housing. This embodiment may benefit from an angled sensor contact plane in the substrate. -
FIGS. 11A and 11B (top and side views, respectively) illustrate analternative implant 190, which includesmain body 192 andsensor 194.Main body 192 can include any of the components set forth herein. Width W of thebody 192 is wider than inFIGS. 9 and 10 , andsensor 194 is oriented degrees relative to the sensor in the embodiment inFIG. 9A .Implant 190 can also be adapted such thatsensor 194 can rotate with respect tomain body 192. In some exemplary embodiments the sensor has a width that is about 0.3 mm to about 2 mm, such as from 0.5 mm to about 1.5 mm. -
FIGS. 12A-12F illustrate anexemplary implant 200 that has more of a square configuration that embodiments above. At least a portion of the implant has more of a square configuration, even if there are one or more arms extending from a main body portion. -
Implant 200 includes anouter cover 210 andinternal portion 220. Any of the description herein relative to covers can also apply to cover 210, and any of the components described above can also be included in internal portion 220 (e.g., battery, processor, antenna, etc.). For example,internal portion 220 can include any or all of the components found ininternal portion 140 shown inFIG. 8A , but they are organized within the implant in a different manner. - Figure is a bottom perspective view with the
cover 210 oninternal portion 220.FIG. 12B is the same view fromFIG. 12A withoutcover 210.FIG. 12C is a front view ofinternal portion 220 withoutcover 210.FIG. 12D is a bottom view withoutcover 210.FIG. 12E is a top view withoutcover 210.FIG. 12F is a topview including cover 210.FIG. 12G is a frontview including cover 210. -
Internal portion 220 includes amain body portion 223 from whichsensor 222 extends. The square configuration can make it easier to implant the implant in certain places in the eye.Main body portion 223 has a square configuration, with Length L and width W being the same dimensions.Body portion 223 can have, however, slightly rectangular configurations as well. Cover 210 similarly has amain body portion 214 with a generally square configuration and anarm portion 212 extending therefrom.Arm 212 has an openend defining lumen 216 sopressure sensor 222 can communicate with the environment. - Internal portion includes
bottom housing 221 and top housing 225 (seeFIG. 12C ) that interface at a hermetic seal, examples of which are described herein. The internal portion also includesantenna 228 disposed in the bottom portion of theinternal portion 220,battery 224,pressure sensor 222, processor 226 (e.g. ASIC), and electrical connect or via 227. - Other aspects of any of the embodiments herein can similarly apply to
implant 200. - It is essential to provide a hermetic seal around the whole implant in order to ensure long term biocompatibility and also eliminate the risk of ocular fluids coming in contact with the miniature electronic circuit boards comprising the implant, potentially causing short circuits and other failures, including corrosion. In some embodiments, a hermetic seal may be formed by encasing the whole implant in a non-permeable material such as glass or Titanium, then closing the casing by means of laser welding, anodic bonding, or other types of sealing process that causes localized heating and fusion but does not cause a significant rise in temperature of the contents of the implant, for example, less than 2 degrees C. A challenge arises when designing a hermetic seal for a pressure sensor module, since it is necessary for the anterior humor of the eye to transmit its pressure to the sensor element inside the hermetically sealed implant in order to obtain reliable measurements of IOP.
-
FIG. 13 illustrates a portion of anexemplary implant 350 in whichpressure sensor 352 is hermetically sealed insidechamber 354. This concept of a fluid-filled chamber in which a pressure sensor is disposed can be incorporated into any implantable device herein.Chamber 354 includes acasing 358 and thinflexible membrane 356, which together define an outer wall of the implant. The implant also includesvias 362 that electrically connectpressure sensor 352 to other implant electronics, as described elsewhere herein. The chamber also includesinert fluid 360 contained within thechamber 354. Thinflexible membrane 356 is thin and flexible enough that it will transmit pressure P exerted by the anterior humor tofluid 360 within the chamber, which transmits the pressure to pressuresensor 352. In some embodimentsflexible membrane 356 can be between 2 microns and 50 microns, such as 2-25 microns, such as such as 2-20 microns, such as 2-15, such as 2-10 microns, such as 5-10 microns. In some embodiments flexible membrane can be made of titanium or parylene. In some embodiments casing 358 can be made of titanium (e.g., TiN) or glass, and optionally coated with ceramic, examples of which are described herein. Examples offluid 360 include, without limitation, nitrogen and silicone oil. The remainder ofimplant 350 can be the same as any of the other implants described herein. - In some embodiments the sensor comprises a piezoelectric sensing element where an inert fluid in the fluid chamber transmits hydrostatic pressure to the sensing element through the flexible membrane. In some embodiments the sensor comprises a capacitative sensing element wherein an inert fluid in the fluid chamber transmits hydrostatic pressure to the sensing element through the flexible membrane.
- Any of the implants herein can have an unfolded length between about 2 mm to about 20 mm, such as between 2 mm and 15 mm, such as between 3 mm and 10 mm, such as about 7 mm. The housing can have a length of between 1 mm and 8 mm, such as between 1 mm and 7 mm, such as between 1 mm and 6 mm, such as between 2 mm and 5 mm, such as about 3 mm, or 3.3 mm.
- The implants herein should be easy to surgically implant, and can optionally be implanted using a scleral tunnel or a clear corneal incision of perimeter less than 3.0 mm, optionally using a punch incision with a needle of outer perimeter preferably less than 1.2 mm, more preferably less than 1.0 mm. The implant should have long term biocompatibility, should not cause tissue erosion, should not cause the loss of corneal endothelium, and should not touch the iris, which will lead to deposition of iris pigment. The implants should provide a routine explantation option. The implants are preferably implanted in the sclera, or the conjunctiva, with the sensor being placed in the anterior chamber, posterior chamber, or inside the lens capsule as in the form of a capsular ring, while it may also be attached to an intraocular lens, the iris, the ciliary bodies, or be sutured to the ciliary sulcus.
- In some embodiments the overall implant dimensions are less than 4.0 mm×1.5 mm×1.0 mm, preferably less than 3.5 mm×1.5 mm×1.0 mm, more preferably less than 2.5 mm×2.5 mm×1.0 mm, and most preferably less than 2.5 mm×2.5 mm×0.500 mm.
- Any of the implants herein can have a folded length (after a portion of the implant is folded, or bent) between about 1 mm and 15 mm, such as between 1 mm and 12 mm, such as between 2 mm and 10 mm, such as between 3 mm and 9 mm, such as between 4 mm and 8 mm, such as between 5 mm and 7 mm, such as about 6 mm.
- Exemplary pressure sensor dimensions can be 0.5 mm-1.5 mm×0.5 mm-2 mm. Off-the-shelf pressures sensors may be used in some embodiments.
- Any of the implant housings herein, such as
bottom housing 221 andtop housing 225 inFIG. 12C (which may also be referred to as “casing” herein) can in some embodiments comprise glass or titanium with a gold or titanium plating (or any other biocompatible metal coating). The flexible connector, in embodiments that include one, can be a variety of suitable materials, such as, without limitation, a polymeric material encapsulated in a biocompatible silicone elastomer. The pressure sensor portion of any of the implants can include a sensor flexible membrane (e.g., Glass/Silicon), with other sides encapsulated in a silicone elastomer. In some embodiments the implant can have a parylene C coating on sensor membrane edges. - In any of the embodiments, any of the housings, such as a top housing or a bottom housing, can have a wall thickness of about 25-200 microns, such as about 50-150 microns, or about 75-125 microns, or about 100 microns. The wall thickness can provide hermeticity over a 10 year lifetime. Any of coatings herein can be about .1micron to about 10 micron, such as about 0.1 micron to about 5 micron. The housings can comprise bonded top and bottom portions interfacing at a seal, as shown. The housings can have any of the following exemplary general shapes or configurations to provide a delivery profile that enables 1.0 mm external diameter: square, oval, circular, C-shaped, rectangular, chamfered, etc. The housings in
FIGS. 5A and 5B , for example, have outer surfaces that are C-shaped, which allows the device to have a smaller profile than it would have with, for example, a more rectangular configuration. - In some embodiments the implant is coated with a biocompatible coating that may be optionally infused with weakly bonded to an anti-inflammatory agent or an anticoagulant, which is illustrated in
FIGS. 14A and 14B . The coating can be comprised of a cross-linked amphiphilic polymer with hydrophobic and hydrophilic segments. Typical polymers include hydrogels, silicone hydrogels and the like, with equilibrium water content ranging from 30% to 90% by weight. The cross-linked polymer comprising the coating folds such that the number density of hydrophilic groups increase towards the outer surface of the coating, while the surface contacting the implant may be richer in hydrophobic groups. This coating may include hydroxyl groups, amino groups, amides, sulfhydryl groups, thiols, as well as ionic moieties such as ammonium groups, alkyl ammonium groups and the like. These groups on the cross linked network comprising the coating are used to hydrogen bond or electrostatically bond anticoagulants such as Heparin sulfonate.FIG. 14A shows anti-inflammatory agents oranticoagulant groups 372, with the remainder of the groups being hydrophilic groups. An example of an anticoagulant is heparin, which is 13-20 kDa. - The hydrogel layer can have a gradient in number density of hydroxyl groups, wherein the gradient is in the opposite direction of the gradient in cross-link density.
- The outer surface of the coating may be patterned or textured in order to promote fixation into the muscle in which the implant is positioned. The design of the texture is optimized to cause a minimal level of fibrosis causing adhesion of tissue to the implant without unduly enhancing immune response to the implant or chronic inflammation. Table 1 includes examples of components that may be included in such coatings.
-
TABLE 1 Cross- Hydrophilic Hydrophobic Linking Monomers Monomers Agents Anticoagulants Hydroxyethyl Methyl Ethylene Glycol Heparin methacrylate methacrylate dimethacrylate Glyceryl mono- Styrene Bis Antithrombin methacrylate Acrylamide Acrylic acid Furfuryl Direct thrombin acrylate inhibitors Methacrylic lepirudin, acid desirudin, bivalirudin, argatroban. Trimethylol propane triacrylate - Any of the power sources herein can be a battery or capacitor, such as a solid-state thin film battery, with an internal electrical connection to the controller, which can be an ASIC.
- Any of the implants herein can have any of the following electronics: a controller such as an ASIC, electrical connections to sensor (such as flexible electronics on a substrate),hermetic via in a housing bottom portion, electrical connections to an antenna (such as flexible electronics on a substrate, and internal connections to the battery, and discrete electronic components (resistance, capacitance and/or inductance). In some embodiments that include an ASIC, the ASIC is ultra-low power to reduce the size of the overall implant.
- In any of the embodiments herein, the ASIC can include a microelectronic circuit comprising a microcontroller, a flash memory, a non-volatile memory and a logic circuit. The logic circuit can include power management and data management modules. The ASIC can include a microelectronic circuit wherein said microelectronic circuit comprises conductive connectors of width in the range 36-360 nanometers.
- Any of the implants herein can also include a H2O getter, adapted to absorb moisture migrating through the housing to extend device lifetime with humidity below target 5000 ppm.
- In some embodiments one or more components of the implant can be configured to correspond, or match, the curvature of one or more anatomical locations within the eye. This can lead to better compatibility within the eye.
- The functionality of one or more components in the device can influence the overall size of the implant. For example, more battery power generally requires a larger battery size, which increases the size of the implant. Similarly, the size of an internal memory can increase as more memory is needed to store sensed data (e.g., temporarily). One or more ASICs can be used to manage the onboard components. It may be generally desirable to make the implant components as small as possible, but without sacrificing desired functionality. Determining how much sensed data is desired and/or the frequency of data sensing can thus influence the overall size of the implant.
- In any of the embodiments herein, the antenna can have a space filling design, meaning that a maximum length of antenna is provided within a specific area, and wherein the antenna is connected to an electrical circuit that can be adjusted for its electrical impedance as a function of its resistive load. Examples of space filling antenna designs can be found in, for example, U.S. Pat. Nos. 7,148,850 and 7,026,997, the disclosures of which are incorporated by reference herein.
- In any of the suitable embodiments herein, the antenna is disposed on a ceramic substrate disposed inside a housing, wherein the antenna has a thickness in the range of 100-500 microns.
- In any of the embodiments herein, the circuit comprising the antenna can have a Q factor in the range of 10-50 under use conditions.
- In any of the embodiments herein, the antenna includes vacuum deposited metal filaments on a ceramic substrate.
- In any of the embodiments herein, the antenna has a conductive length of not less than 15 mm and not more than 100 mm.
- In any of the embodiments herein, the antenna is adapted so that it transmits electromagnetic energy at a frequency that is not harmful to the human body.
- Any of the implants herein can have more than one pressure sensor therein, or secured thereto.
-
FIG. 15 illustrates anexemplary implant 300 that includes sensor and electronic 302 mounted on aglaucoma draining device 304, such as those manufactured by SOLX™.FIG. 15 illustrates a device that can both monitor pressure (using any of the electronic components and configurations herein in portion 303) and treat high TOP. Additional sensors can be implemented to detect oxygenation and proteins. - In any of the embodiments herein, the implant is adapted to sense TOP of an eye, or a portion of the eye. Any of the implants herein can include erasable memory. In some embodiments the system includes one or more external interrogation devices (“EID”s) that are disposed outside of the eye and can be adapted to communicate (preferably wirelessly) directly or indirectly with the implant. The EID is used to recharge the battery disposed in the implant, receive intraocular pressure data from the implant and reprogram the firmware embedded in the ASIC of the implant, when required. Communication between the implant and the EID follows a protocol, and example of which is shown in
FIG. 16 . This protocol involves encrypted data exchange, said encryption being compliant with all applicable Governmental regulations controlling confidentiality of medical information. Such a communication protocol also includes a handshake between the EID and the implant, the EID being the Master and implant being the Slave in this protocol. The exemplary protocol inFIG. 16 includes the following steps: 1) I am ready to transmit power and receive data; 2) I am ready to receive power, receive data, and I have data to transmit; 3) Transmission of data for initialization (code, time stamp, resonance frequency); 4) Data transmission (always recharging first step, when completed, data transmission (second step), when completed data transmission from External Unit to Implant (third step)); 5) Data transmission complete; recharging can begin in 2 seconds; 6) Wireless power transmission; 7) Threshold voltage reached, stop power transmission; 8) I am ready to receive data transmission (data for LUTs; reprogramming of firmware); 9) I have data/no data to transmit; 10) Data transmission, ifstep 9 gives code for data to transmit. - The one or more EIDs can receive information from the implant, such as pressure data (raw or processed) or other data indicative of pressure. The EIDs can also transmit information to the implant, such as instructions for programming or reprogramming some operational functionality of the implant (sensing software in the implant). One or more EIDs can also communicate with other EIDs, or external databases. An EID can also transfer power to the implant.
- In some embodiments the system includes a patient EID (e.g., smartphone or a dedicated electronic device or an add-on device to a smartphone), which can be used or controlled by the patient. A patient EID can be used to charge the implant, receive data from the implant (e.g., by querying the implant), and optionally reprogram one or more algorithms stored in the implant. A patient EID can be wearable (e.g., wristband, watch, necklace) or non-wearable (e.g., smartphone, smartphone add-on, bedside device).
- Systems herein can also include one or more physician EIDs, which can be wearable or non-wearable (e.g., dedicated electronic device, or laptop, smartphone or tablet add-on). For example, a physician can have access to one handheld EID (e.g., smartphone or tablet add-on), and have access to another medical personnel EID (e.g., a laptop computer with additional hardware and software capabilities). Any of the EIDs herein can be adapted to perform any of the EID functions described herein.
- System software, on one or more of the EIDs, can be adapted to download and/or upload sensed pressure data, or information indicative or sensed pressure data to one or more EIDs or to the implant. System software includes software for data storage, data processing, and data transfer. System software can also facilitate communication between the patient EID and one or more physician EID (or other remote device).
- The systems herein can also include one or more software and/or firmware applications to collect, compile, and/or store individual sensor data (e.g., sensor measurements) for diagnostic or treatment evaluation support by the medical personnel (e.g., ophthalmologist). The software and/or firmware may exist on one or more EIDs, or in some instances may be disposed on or more implantable devices. The systems herein can also include one or more software applications to collect and/or compile multiple sensors data as a basis for medical data analysis, allowing support for, e.g., predictive medicine.
- Management of data can include processing of raw signals to, e.g., filter noise and enhance signal to noise ratio, application of algorithms that recognize and select a true pressure data from spurious signals, further processing of data to, e.g., recognize and
document 1 hour to 30 day trends in pressure, and reprogramming of the ASIC and device firmware in response to specific data trends or command by caregiver. - Theoretically, a truly continuous monitoring of IOP requires continuous monitoring of IOP at a frequency exceeding the most rapid spike in IOP recorded (approx. 30 Hz). In reality, the data generated by such a sensor will be of such a magnitude that it will be difficult to manage even with frequent downloading of data, and will also require a large battery in order to manage the daily power consumption of such a device. In some embodiments an optimum amount of pressure data is therefore collected per day, based on patient needs, needs of treatment, upper limit of power available, and size of the memory units in the device.
- In some embodiments the resolution and accuracy of IOP data range from 0.2 mmHg to 1.0 mmHg and form 0.5 mmHg to 2 mmHg, respectively. In some embodiments the frequency of data acquisition is minimum 2/day to
maximum 1/15 min. In some embodiments the frequency of recharge is less frequently than 1/day. In some embodiments the frequency of data transmission to a caregiver can be once a day or more. In some embodiments wireless recharging and data exchange is performed using inductive coupling or electro-magnetic coupling among magnetic and/or electric antennas respectively, uses a body safe frequency and intensity, and with minimum attenuation by human tissue. The implants should have a 10 years life of battery, and have hermetically sealed package. - The sensed data and/or data indicative of the sensed data can be stored in one or more proprietary databases. In some embodiments all of the database information must be reviewed by a physician before being included in the database. In these embodiments the patients do not have access to the database. One or more databases can store time histories of sensed pressure measurements, or time histories of data indicative of sensed pressure.
- The one more databases can include lookup tables with threshold pressures values, such that future sensed pressure data can be compared to the data in the lookup tables. The lookup tables can be for an individual or across a population of individuals. The lookup tables can be updated with new pressure data from one or more implants and one or more individuals. In some embodiments threshold levels can be a factor relative to therapy, optionally automatic drug delivery or a drug regimen. In some embodiments the sensed data can be used in a closed loop treatment loop. For example, pressure sensed over time can be input to a closed loop patient therapy protocol, such as closed loop drug therapy protocol.
- The one or more remote databases can be a repository of all patient data, supplied by care givers, and encrypted; scalable; compatible with HIPPA regulations; and accessible to third parties
-
FIG. 17 illustrates a merely exemplary schematic of operation of an exemplary autonomous intraocular pressure sensor system.System 250 includesimplant 252, one ormore EID 262,remote database 274, and SWAP 276. Not all aspects of the system need to be included in the system. Implant 252 (which can be any implant herein), includes wireless powering device 253 (e.g., RF powering), energy storage 254 (e.g., rechargeable battery), processor 257 (e.g., ASIC),pressure sensor 255,pressure acquisition software 256,memory 258, and data transmitter 259 (e.g., RF data transmitter).EID 262 can provide power to implant 252, and can have directional data transfer withimplant 252.EID 262 includespower interface 263,data interface 264,controller 266,non-volatile memory 265,power management 267, and communication module 268 (e.g., wireless comm module). -
FIG. 21 illustrates a further exemplary schematic of operation of an autonomous intraocularpressure sensor system 401, includingimplant 400,EID 402,database 404 andSWAP 406. As shown,pressure sensor 405 senses pressure and sensed pressure or data is communicated toelectronics 410.Power management 412 is in communication withwireless transfer function 414 andelectronics 410.EID 402 can have any functionality described herein. - The disclosure herein also includes methods of delivering, or inserting, any of the implants herein. The disclosure herein also describes one or more surgical tools adapted for implanting the implant in or on the eye of a patient, and optionally a similar set of tools for implantation in animals for the purpose of validation studies. It is important that the implant, during delivery and after being implanted, not touch the corneal epithelium since the epithelial cells will be destroyed if they are touched.
- The implantation of any of the implants herein in an eye will generally require one or more dedicated surgical tools and procedures. These implantation procedures will generally lead to minimal to no degradation of the patient's vision (e.g., by inducing astigmatism). In view of this, implantation through a needle (e.g., large gauge) is preferred over an incision. In some embodiments the entire implant is delivered through a needle. In some embodiments the needle is 13G needle, and in some embodiments it can be a 19-21G needle. An exemplary benefit of delivering through a needle is that no suturing is needed because no incision needs to be made.
- Alternatively, the implantation of any implant herein can be combined with another surgical intervention, such as IOL implantation or in conjunction with other glaucoma drainage devices. In those embodiments, the implant and method of implant should be compatible with the incision already required for the implantation (e.g., IOL). In case of malfunction and/or risk to the patient, the implant is preferably also explantable with a similar, minimal invasive surgery, using dedicated tools. All tools and procedures are preferably compatible with both the right and left eye.
- The implant is ideally positioned such as to not cause any visual obstruction, no degradation of any function of the eye, and generally not alter or aggravate the TOP of the patient (although some minor change in TOP may be caused). Additionally, in some embodiments, the implantation procedure does not deteriorate the vision of the patient by more than 0.25 diopters. An injection of the device (punch rather than incision) is preferred.
-
FIG. 18 illustratesexemplary implant locations 300, including but not limited to the anterior and posterior chamber, below the conjunctiva, and in Schlemm's canal.FIGS. 19A and 19B (side and front views, respectively) illustrates the anatomy of a portion of the eye, illustrating possible locations for the one or more implants. In some embodiments the implant includes two portions spaced from each other, and the implant is sized and configured such that the pressure sensor can be positioned in the anterior chamber while the implant housing is positioned in the suprachoroidal space. In some embodiments the implant is stabilized in placed due to, at least partially, the configuration of one or more components of the implant, and the interface with a portion of the eye. In some embodiments, fibrotic response can assist in keeping the implant, or a portion of the implant, in place. - Exemplary implantation procedures will now be disclosed. These exemplary procedures include an implantation of the sensor part of the implant in the anterior chamber angle, while the rest of the implant is positioned in the scleral/suprachoroidal space. These exemplary procedures include a punch incision and can be performed either at a slit lamp or in an operating room. The individual in which the implant is implanted is referred to generally herein as “patient,” but can include any person or animal, whether suffering from a medical condition or not. An eye may have more than one implantable device implanted therein. For example, it may be beneficial to have multiple devices in different locations to sense pressure at different locations within the eye, particularly if pressure varies from location to location within the eye.
- A first exemplary procedure includes implantation through the conjunctiva. An eye is prepped with
Betadine 5% sterile Ophthalmic solution. Topical anesthesia is then instilled to the surface of the eye.Lidocaine 1% preservative free solution is then injected under the conjunctiva in the area of insertion of the implant. The patient will then look opposite to the site of insertion (e.g., a patient looks up for insertion of the implant in inferior quadrants). The insertion device (e.g., needle) holding the sensor is entered through the conjunctiva approximately 3.5 mm from the limbus, into the sclera 2.5 mm from the limbus, and then directed to the anterior chamber angle. Once the sensor in observed in the anterior chamber, the needle is withdrawn and the tail of the implant will remain within the sclera with the sensor portion in the anterior chamber angle. The entrance of the needle will be watertight and there will be not be a need for suturing. - A second exemplary procedure includes implantation through cornea/paracentesis. An eye is prepped with
Betadine 5% sterile Ophthalmic solution. Topical anesthesia is then instilled to the surface of the eye.Lidocaine 1% preservative free solution is injected in the anterior chamber. A paracentesis is then made opposite to the area of insertion of the implant. The insertion device then enters through the paracentesis and is advanced to the opposite angles, and the tail of the implant is inserted in the suprachoroidal space with the sensor portion of the implant remaining in the anterior chamber angle. The inserter is removed from the eye and the paracentesis is watertight and there is no need for suture placement. - When used in humans, the implantation of a wireless implant with sensor may be used to improve a patient's glaucoma treatment, either for early diagnostics or at the medication stage. The implants may also be used to gather data, whether in animals or humans.
- Taking into account that patient compliance is one of the major challenge in IOP treatment, and in view of the average age of glaucoma patients, the periodic (e.g., regular) measurements of the IOP are preferably done with minimal patient actions (autonomously). The preferred implementation of this is through an active implant, which carries out measurements at optionally fixed time intervals utilizing an internal power source/power storage and internal memory/data storage, and is read out on a less regular basis by one or more EIDs, or alternatively with an EID which is capable of performing remote measurements at such a range that the patient is free in their movements and daily activities. In some embodiments the data transmission to physician EID can occur autonomously. For example, sensed data can be autonomously transmitted from the implant to a bedside EID at night, and then autonomously transmitted.
- After implantation, the implant sensor senses pressure. Pressure can be sensed continuously (sensed during the entire time the implant is positioned in the patient, without interruption), or non-continuously. The implant can optionally have a continuous sensing “mode,” in which the implant is adapted to sense continuously, but the implant can also be taken out of the continuous mode, when switched to a different mode (e.g., no sensing, or a non-continuous sensing mode). When sensed non-continuously, it can be sensed periodically, either at regular intervals or non-regular intervals (e.g., sensed in response to detected events that do not happen with any known regularity). Exemplary regular intervals include one or more times a minute (e.g., 1, 2, 5, 10, 20, or 30 times a minute), one or more times a days (e.g., once, twice, five, twenty-four, 48 or 96 times a day). When sensed non-continuously, there may be epochs of time during which there is continuous sensing for a limited period of time, such as 1 minute of sensing, and then 59 minutes without sensing. An example of substantially continuous sensing is, for example, 30 times a minute. In some embodiments the pressure is sensed 1 time/day, or less (e.g., 1 time every two days). In some embodiments the frequency of sensing is between continuously and 2 times/day.
- In some embodiments the implant is adapted to sense pressure at a particular frequency, but stores in memory only a subset of the sensed pressures. Sensed data can be stored in, for example, a first in first out manner.
- The required IOP measurement pressure range can be, in some embodiments, lmmHg around ambient pressure and up to an overpressure of approximately 50 mmHg above ambient pressure.
- The recorded data can be stored in a memory and transmitted periodically to an ophthalmologist (e.g., EID) for treatment evaluation. It may be beneficial for the patient not to have direct access to the IOP data. In some embodiments, in which the patient has an EID, the patient's EID is adapted to do one or more of the following: retrieve stored IOP data from the IOP implant; retrieve operational status of the implant and any error messages; and transfer power to the IOP implant to charge the power storage component.
- In embodiments in which an IED provides power and data transfer to the implant, they are both preferably achieved wirelessly, typically over an RF link. The EID can receive this data and status of the implant, and communicate it to the ophthalmologist (or other second EID) for treatment evaluation support. In addition, the data collected by any or all EIDs can be compiled in databases, optionally in an anonymized format, in order to use the collective patient data to support applications in predictive medicine and e-health.
- In embodiments in which medical personnel have access to an EID, that EID can be adapted to perform the same tasks as the patient EID, but it may additionally be adapted to perform any of the following: program some basic operational functions of the implant (e.g., measurement interval), and allow calibration of the implant's IOP values against e.g., a traditional tonometer.
- In some embodiments an external interrogation unit has a resonant circuit for wireless charging of the implant; ASIC for power and data management; can be mounted in furniture, bed, eyeglasses for close access to the implant coil; adapted to reprogram the firmware, algorithm in the implant; can have multiple units for patient convenience; and can be portable.
- Sensor readings from one or more implants may need to be calibrated based on, for example, their position in the eye. In some embodiments the position of the one or more wireless IOP sensors is such that the pressure reading at the sensor is directly linked to, or can be calibrated back to, the fluid pressure in the anterior chamber. Currently, intraocular pressure is measured by a device applying a force to the anterior surface of the cornea. It may be that sensor readings sensed within the eye, or even at different locations within the eye, result in pressure sensor readings that are different than are currently measured at the anterior surface of the cornea. Sensor readings obtained with implants herein may thus need to be calibrated with existing pressure readings taken at the anterior surface of the cornea. Different sensor locations may also need to be calibrated individually, particularly if sensor readings are different at different locations within the eye. Additionally, pressure readings may be more accurate or provide more reliable information at particular locations within the eye.
- Patient to patient variability, which can be variability across the board or at particular locations, can require calibration and/or recalibration for each patient.
- In some embodiments more than one sensor may be implanted in an eye, and the different sensors may obtain unique sensor readings. The system can be adapted to use the different sensor data to, for example, provide a pressure difference between two sensors, and improved patient therapy or diagnostics.
- In some embodiments, in order to use the collected pressure data (patient-specific or anonymized), a remote database (e.g., cloud database) of the recorded IOP values exists. The database can interact with one or more EIDs and/or clinicians, and can be used to process the IOP data.
- While the implant generally only communicates when interrogated by an EID (due to power constraints), in some modified embodiments the implant may be adapted with sensed data event detection, generally requiring a processing component. For example, when sensing pressure, the implant can be adapted to detect a threshold pressure or other event. The event detection can trigger a variety of actions, such as, for example, automatic drug delivery, storing future sensed data after the detected event, and automatic transmission of data to one or more EIDs.
- In some embodiments the implant and one or more EIDs can be adapted so that the one or more EIDs can reprogram one or more functions of the implant. For example, an implant's sensing frequency, event detection, sensed threshold value, etc., can be reprogrammed by the one or more EIDs. Reprogramming can occur in response to a change in the database lookup tables, for example. Reprogramming can also occur in response to data sensed from the particular patient.
- Any of the implants herein can have an internal power source that can be recharged using an EID. In some embodiments charging is done via an inductive or electromagnetic coupling with emitted powers from the EID in the 10-30 mW range, such as 25 mW, or in the range of 1 W to 5 W, such as 3 W. In some embodiments the EID can transmit power and data to the implant.
- In some embodiments the length of the antenna in the implant is 30 mm or less, such as 25 mm or less, such as 15 mm or less, such as 10 mm or less, and a height of 3 mm or less, such as 2.0 mm or less, such as 1.5 mm or less.
- This exemplary power transfer data shows feasibility for these antenna designs, with the exemplary coiled antennas more efficient than the straight antenna. Initial prototypes have used the MIL-STD 883 for hermeticity requirements. The norm specifies 5000 ppm of H2O vapour as upper limit. Rationale: 5000 ppm is condensation point of water vapour at 0 deg C. With less than 5000 ppm of H2O, water will never condensate: above 0 deg C. it is vapour, below 0 deg C. the condensed water will freeze. No liquid water can be present below 5000 ppm at any temperature. Note: At eye temperature, the dew point is much higher than 5000 ppm, namely 25000 ppm.
- The following describes some optional features of any of the implant housings (e.g., around a battery and ASIC) herein: Any of the implants herein can achieve <5000 ppm H2O over a 10 year lifetime. There may be a trade-off between housing thickness and permeability: thicker housing walls provide lower permeability but cause a larger implant volume. A larger inner volume gives more allowed H2O before reaching 5000 ppm but for larger implant volume. It may be preferable for the housing material for electronics and battery to be glass, ceramic or metal (Ti) or any metal/glass/ceramic combination. Additional conformal barriers like Parylene C are also considered. Any of the implants herein can include a H2O getter. H2O getter can be a solid/polymer that binds H2O molecules entering implant, lowering internal H2O pressure (until full). The H2O getter can extend lifetime below 5000 ppm at a given permeability.
- The disclosure herein includes methods of use in animals (e.g., rabbits, mice, rat, dog) aimed at initial IOP data collection and serving for validation studies for humans or veterinary applications. The disclosure herein also includes human uses, which can be aimed at collecting regular patient IOP values to be used for any of diagnostics support, drug selection support, and evaluation of patient compliance to glaucoma treatment. The rabbit eye is a standard biomedical model for validating human intraocular implants as it has similar dimensions (see
FIGS. 20A-20B ), but shows accelerated fibrotic and inflammatory behavior with respect to human eyes. Any of the WIPS herein can thus be implanted in rabbit (or other animal) eyes. The implantation of implantable device in animals can provide any of the following: data can be gathered for glaucoma pharmaceutical development programs; data collected by a device in a rabbit's eye can be used as clinical evidence for a future human product; and valuable usability inputs can be generated. -
FIGS. 20A and 20B show human (a), and rabbit eye (c) to scale, including schematic representation of the lens (yellow), retina (red) and vitreous and aqueous bodies (blue). - An TOP device that is implanted in a rabbit should therefore, in some uses, be the same or nearly the same as a current or future human device. Some difference between rabbit implants and human implants may include one or more of: the implant location in a rabbit eye may be different than in the human eye in view of the dimensional differences of anterior and posterior chamber of a human vs. rabbit eye (the location should be, however, medically representative (IOP, fibrosis, inflammation)); the implantation time may be shorter with the rabbit compared to the human application; the surgical tools may differ in size to match the dimensions of the rabbit's eye, but not in function compared to the tools for human implantation; and the regulatory requirements that apply for rabbit implantation may differ from those for human implantation. All other aspects can be the same as those of human implants described in the following section.
- The system and implants herein can also be used for research purposes to investigate changes in intraocular pressure due to certain activities, such as exercise, or sleep, or drug therapy.
- Additional Examples. The following are additional examples of the disclosure herein.
- An optionally autonomous, wirelessly connected, intraocular pressure sensing implant, wherein said implant is less than 3.5 mm in its longest dimension.
- The implant of any of the additional examples herein wherein said implant has an internal rechargeable power source that can provide operating power for at least one half day (12 h) of operation.
- The implant of any of the additional examples herein wherein said power source is a rechargeable battery.
- The implant of any of the additional examples herein wherein said implant has power and data management integrated circuits that consume less than 50% of its stored power in resistive losses.
- The implant of any of the additional examples herein wherein said implant utilizes at least one application specific integrated circuit for power and data management.
- The implant of any of the additional examples herein wherein said implant comprises a sensor that senses intraocular pressure and collects pressure data more than once every 12 hours and no more than once every minute.
- The sensor of any of the additional examples herein wherein said sensor operates at a frequency of 30 Hz or more.
- The implant of any of the additional examples herein wherein said ASIC is controlled by firmware that is reprogrammable by an external unit via wireless communication of data subsequent to implantation of any of the implants herein.
- The implant of any of the additional examples herein wherein said ASIC downloads data to said external unit that is programmed to receive said data.
- The implant of any of the additional examples herein wherein said ASIC actuates commencement of wireless recharging from said external unit upon receipt of a trigger signal.
- The implant of any of the additional examples herein wherein a trigger signal may be transmitted from an external unit.
- The implant of any of the additional examples herein wherein said trigger signal may be generated inside said ASIC when the output voltage of said rechargeable battery of
claim 3 drops below a threshold voltage that is above the voltage at which the battery shuts down. - The implant of any of the additional examples herein wherein said implant is rendered biocompatible by being hermetically sealed.
- The implant of any of the additional examples herein wherein said sensor is periodically actuated by an ASIC.
- The implant of any of the additional examples herein wherein a trigger can be externally or internally generated.
- The implant of any of the additional examples herein wherein a trigger signal when internally generated, is reprogrammable.
- The implant of any of the additional examples herein wherein data is processed and filtered in firmware in an ASIC.
- The implant of any of the additional examples herein wherein data is further processed, analyzed and encrypted in a data processing module in an external unit.
- The implant of any of the additional examples herein wherein data is downloaded to a smart phone or a tablet or a dedicated electronic device (e.g., the EID).
- The implant of any of the additional examples herein wherein data is transmitted from an EID, a smart phone or a tablet to the computer of the caregiver.
- The implant of any of the additional examples herein wherein data is transmitted by the caregiver to a remote data base.
- An implant sized to be stabilized within an eye, the implant comprising an intraocular pressure sensor.
- An implantable intraocular pressure sensor, comprising a pressure sensor and electronics coupled to the pressure sensor.
- Any of the claimed implants, adapted to be positioned in any of the anatomical shows or described herein.
- A method of positioning an intraocular pressure implant, comprising a sensor, in an eye.
- A method of sensing intraocular pressure continuously, substantially continuously, or periodically, with an implantable intraocular sensor sized and configured to be stabilized within an eye.
- Any of the claimed methods, further comprising transmitting information, either pressure data (e.g., raw or processed) or information indicative of pressure data wirelessly to an external device.
- Any of the methods of calibrating an implantable pressure sensor herein.
- A method of sensing pressure in an eye with an implantable device, wherein the implantable device is adapted to process the sensed pressure.
- The implant of any of the additional examples herein wherein the implant comprises a memory module that further comprises non-erasable and/or reprogrammable memory elements.
- The implant of any of the additional examples herein wherein the implant comprises a controller that controls its pressure sensing, data collection, processing, storage and transmission, and recharging operations.
- The implant of any of the additional examples herein wherein a wireless connection between said implant and an external unit is operated at below 6 GHz, e.g., at 868 MHz, 900 MHz or 2.4 GHz.
- The implant of any of the additional examples herein wherein the wireless connection between implant and external unit comprises electro-magnetic or inductive coupling between a transmitting and a receiving antenna.
- The implant of any of the additional examples herein wherein the wireless connection between implant and external unit utilizes one or more antennas which can be e.g., straight, coiled, or flat.
- The implant of any of the additional examples herein wherein the wireless connection between implant and external unit coupling has a system Q factor not less than 10 and not exceeding 100.
- The implant of any of the additional examples herein wherein a transmitter coil transmits wireless power not exceeding 25 milliwatts.
- The implant of any of the additional examples herein wherein recharging of the implant occurs at any distance between 2 cm and 2 meters.
- The implant of any of the additional examples herein wherein preferred modes of charging the implant are either at 2-5 cm over 1 hour or 0.5-2.0 meters over 8 hours.
- The implant of any of the additional examples herein wherein data is transmitted by the EID, the patient's smartphone or tablet to a remote data base.
Claims (21)
1. An implantable pressure sensor assembly, comprising:
a flexible membrane including a parylene polymer and forming a hermetic seal sealing a chamber;
a pressure sensor disposed within the chamber;
an inert fluid disposed in the chamber and in direct contact with the pressure sensor; and
a coating disposed on an outer surface of the flexible membrane,
wherein the flexible membrane is adapted to transmit pressure from an external environment to the inert fluid inside the hermetic seal.
2. The assembly of claim 1 , wherein the flexible membrane has a thickness of about 2 μm to about 50 μm.
3. The assembly of claim 1 , wherein the inert fluid is configured to transmit hydrostatic pressure to the pressure sensor through the flexible membrane.
4. The assembly of claim 1 , wherein the pressure sensor is configured to measure a pressure of about ambient pressure ±1 mmHg to about ambient pressure+50 mmHg.
5. The assembly of claim 1 , wherein the coating comprises at least one of ceramic or parylene.
6. The assembly of claim 1 , wherein the coating comprises a hydrogel with a gradient in at least one of number density of hydroxyl groups or cross-link density.
7. The assembly of claim 6 , wherein the hydrogel is infused with a therapeutic agent configured to be released from the hydrogel over a period of at least 10 days following implantation of the assembly into a body.
8. The assembly of claim 6 , wherein the hydrogel is impregnated with at least one therapeutic agent to reduce clotting and/or inflammatory response.
9. The assembly of claim 1 , wherein the parylene polymer is parylene C.
10. The assembly of claim 1 , further comprising:
a rechargeable power source electrically coupled to the pressure sensor;
an antenna electrically coupled to the rechargeable power source; and
an application-specific integrated circuit (ASIC) electrically coupled to the rechargeable power source and the pressure sensor.
11. The assembly of claim 10 , wherein the antenna is part of a first circuit adapted to supply power to the rechargeable power source, and the antenna is also part of a second circuit adapted to transmit data to an external device.
12. The assembly of claim 10 , wherein the ASIC comprises a microcontroller, a flash memory, a non-volatile memory, and a logic circuit.
13. A method of forming an assembly comprising:
creating a hermetic seal around a chamber containing a pressure sensor with a flexible membrane including a parylene polymer;
disposing an inert fluid inside of the chamber and in direct contact with the pressure sensor; and
depositing a coating on an outer surface of the flexible membrane.
14. The method of claim 13 , wherein depositing the coating comprises depositing at least one of a ceramic layer or a parylene layer.
15. The method of claim 13 , wherein depositing the coating comprises depositing a hydrogel with a gradient in at least one of number density of hydroxyl groups or cross-link density.
16. The method of claim 13 , wherein depositing the coating comprises depositing a hydrogel infused with a therapeutic agent configured to be released from the hydrogel over a period of at least 10 days following implantation of the assembly into a body.
17. The method of claim 13 , wherein depositing the coating comprises depositing a hydrogel impregnated with at least one therapeutic agent to reduce clotting and/or inflammatory response.
18. The method of claim 13 , further comprising:
electrically coupling a rechargeable power source to the pressure sensor;
electrically coupling an antenna to the rechargeable power source; and
electrically coupling an application-specific integrated circuit (ASIC) to the rechargeable power source and the pressure sensor.
19. A method comprising:
implanting a pressure sensor assembly into a mammalian body, the pressure sensor assembly including a flexible membrane forming a hermetic seal about a chamber, a pressure sensor disposed in the chamber, and an inert fluid disposed in the hermetic seal and in direct contact with the pressure sensor;
transmitting a hydrostatic pressure from the body to the inert fluid via the flexible membrane;
transmitting the hydrostatic pressure from the inert fluid to the pressure sensor; and
measuring the hydrostatic pressure with the pressure sensor.
20. The method of claim 19 , wherein the pressure sensor assembly further includes a pressure sensor, a rechargeable power source, and an antenna and the method further comprises:
wirelessly recharging the rechargeable power source electrically coupled to the pressure sensor via the antenna; and
wirelessly transmitting pressure data measured by the pressure sensor to an external device via the antenna.
21. The method of claim 19 , further comprising:
following implanting, releasing a therapeutic agent from a coating disposed on the pressure sensor assembly over a period of at least 10 days.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/937,062 US20230024683A1 (en) | 2016-05-31 | 2022-09-30 | Implantable intraocular pressure sensors and methods of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662343593P | 2016-05-31 | 2016-05-31 | |
PCT/US2017/035247 WO2017210316A1 (en) | 2016-05-31 | 2017-05-31 | Implantable intraocular pressure sensors and methods of use |
US201816302750A | 2018-11-19 | 2018-11-19 | |
US17/937,062 US20230024683A1 (en) | 2016-05-31 | 2022-09-30 | Implantable intraocular pressure sensors and methods of use |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/035247 Continuation WO2017210316A1 (en) | 2016-05-31 | 2017-05-31 | Implantable intraocular pressure sensors and methods of use |
US16/302,750 Continuation US11497399B2 (en) | 2016-05-31 | 2017-05-31 | Implantable intraocular pressure sensors and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230024683A1 true US20230024683A1 (en) | 2023-01-26 |
Family
ID=60477972
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/302,750 Active 2040-03-05 US11497399B2 (en) | 2016-05-31 | 2017-05-31 | Implantable intraocular pressure sensors and methods of use |
US17/937,062 Pending US20230024683A1 (en) | 2016-05-31 | 2022-09-30 | Implantable intraocular pressure sensors and methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/302,750 Active 2040-03-05 US11497399B2 (en) | 2016-05-31 | 2017-05-31 | Implantable intraocular pressure sensors and methods of use |
Country Status (6)
Country | Link |
---|---|
US (2) | US11497399B2 (en) |
EP (1) | EP3463044A4 (en) |
JP (1) | JP2019518546A (en) |
CN (2) | CN114532976A (en) |
CA (1) | CA3024891A1 (en) |
WO (1) | WO2017210316A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11684703B2 (en) | 2018-02-20 | 2023-06-27 | Qura, Inc. | Coatings for implantable devices |
US11602427B2 (en) | 2018-03-30 | 2023-03-14 | Qura, Inc. | Intraocular lenses including an intraocular pressure sensor |
DE102018204949A1 (en) * | 2018-03-30 | 2019-10-02 | Bernhard Clasbrummel | Implant and method for the diagnosis and / or treatment of inflammatory tissue conditions |
WO2019216945A1 (en) | 2018-05-07 | 2019-11-14 | Qura, Inc. | Business methods based on providing monitoring services and access to information to caregivers, patients with implanted pressure sensors and distributors |
WO2019219193A1 (en) * | 2018-05-16 | 2019-11-21 | Implandata Ophthalmic Products Gmbh | Partially flexible device for determining interocular pressure for implanting in the human body |
US11806278B2 (en) | 2018-08-30 | 2023-11-07 | Qura, Inc. | Implantable intraocular drug delivery devices |
WO2020066095A1 (en) * | 2018-09-27 | 2020-04-02 | 株式会社村田製作所 | In vivo implanted medical device |
WO2020236139A1 (en) | 2019-05-17 | 2020-11-26 | Qura, Inc. | Intraocular lenses with intraocular pressure sensors and methods of manufacture |
DE102019126959A1 (en) * | 2019-10-08 | 2021-04-08 | Implandata Ophthalmic Products Gmbh | Arrangement for changing intraocular pressure in vivo |
CN110917502B (en) * | 2019-11-14 | 2021-11-30 | 中山大学 | Oral cavity implanted wireless power supply luminous micro device capable of promoting dental tissue repair |
US20210186429A1 (en) * | 2019-12-20 | 2021-06-24 | Glaukos Corporation | On-demand intraocular physiological sensor with trabecular bypass flow |
JP2022104715A (en) * | 2020-12-29 | 2022-07-11 | 株式会社トプコン | Ophthalmologic information processing system, ophthalmologic information processing server, ophthalmologic information processing program, and ophthalmologic information processing method |
KR20230107946A (en) * | 2022-01-10 | 2023-07-18 | 엘에스일렉트릭(주) | Wireless sensor apparatus |
Family Cites Families (208)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4206762A (en) | 1976-06-21 | 1980-06-10 | Cosman Eric R | Telemetric differential pressure sensing method |
US4834750A (en) | 1987-09-17 | 1989-05-30 | Ioptex Research, Inc. | Deformable-elastic intraocular lens |
US4922913A (en) | 1987-11-12 | 1990-05-08 | Waters Jr George E | Intraocular pressure sensor |
US5005577A (en) | 1988-08-23 | 1991-04-09 | Frenkel Ronald E P | Intraocular lens pressure monitoring device |
US5179953A (en) | 1991-08-27 | 1993-01-19 | Jermik Systems, Ltd. | Portable diurnal intraocular pressure recording system |
US5629577A (en) | 1994-07-15 | 1997-05-13 | Micro Medical Devices | Miniature linear motion actuator |
US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
US6083174A (en) | 1997-02-13 | 2000-07-04 | Sican Gmbh | Implantable measuring unit for intracorporal measurement of patient data |
DE19728069C1 (en) | 1997-07-01 | 1999-02-11 | Acritec Gmbh | Device for measuring intraocular pressure |
MC2461A1 (en) | 1997-09-26 | 1998-12-18 | Exsymol Sa | Ophthalmic and implantable devices covered with a coating and methods for producing the latter |
US6168575B1 (en) | 1998-01-29 | 2001-01-02 | David Pyam Soltanpour | Method and apparatus for controlling intraocular pressure |
US6152885A (en) | 1998-04-30 | 2000-11-28 | Medtronic, Inc. | Barometric pressure sensor for use with implantable absolute pressure sensor |
SE9803481D0 (en) | 1998-10-13 | 1998-10-13 | Pharmacia & Upjohn Ab | Photocurable siloxane polymers |
US6193656B1 (en) | 1999-02-08 | 2001-02-27 | Robert E. Jeffries | Intraocular pressure monitoring/measuring apparatus and method |
AU767526B2 (en) | 1999-04-26 | 2003-11-13 | Gmp Vision Solutions, Inc. | Trabeculotomy device and method for treating glaucoma |
US6802811B1 (en) | 1999-09-17 | 2004-10-12 | Endoluminal Therapeutics, Inc. | Sensing, interrogating, storing, telemetering and responding medical implants |
DE19945879C2 (en) | 1999-09-24 | 2002-01-03 | Acritec Gmbh | Device for measuring the intraocular pressure with a foldable implant |
US7246069B1 (en) | 1999-10-15 | 2007-07-17 | Ue Systems, Inc. | Method and apparatus for online health monitoring |
US6579235B1 (en) | 1999-11-01 | 2003-06-17 | The Johns Hopkins University | Method for monitoring intraocular pressure using a passive intraocular pressure sensor and patient worn monitoring recorder |
US6939299B1 (en) | 1999-12-13 | 2005-09-06 | Kurt Petersen | Implantable continuous intraocular pressure sensor |
ES2246226T3 (en) | 2000-01-19 | 2006-02-16 | Fractus, S.A. | MINIATURE SPILL FILLING ANTENNAS. |
US6772988B2 (en) | 2000-03-31 | 2004-08-10 | Bausch & Lomb Incorporated | Method and mold to control optical device polymerization |
US6749568B2 (en) | 2000-08-21 | 2004-06-15 | Cleveland Clinic Foundation | Intraocular pressure measurement system including a sensor mounted in a contact lens |
US6447449B1 (en) | 2000-08-21 | 2002-09-10 | Cleveland Clinic Foundation | System for measuring intraocular pressure of an eye and a MEM sensor for use therewith |
WO2002019949A2 (en) | 2000-09-07 | 2002-03-14 | Allergan Sales, Inc. | Intraocular lens with a posterior lens portion |
US7273457B2 (en) | 2000-10-16 | 2007-09-25 | Remon Medical Technologies, Ltd. | Barometric pressure correction based on remote sources of information |
US6764446B2 (en) | 2000-10-16 | 2004-07-20 | Remon Medical Technologies Ltd | Implantable pressure sensors and methods for making and using them |
EP1351600A1 (en) | 2001-01-17 | 2003-10-15 | Humanoptics AG | Implant for determining intra-ocular pressure |
DE10106881C2 (en) * | 2001-02-14 | 2003-04-30 | Campus Micro Technologies Gmbh | Intraocular implant for telemetric determination of intraocular pressure |
US6981958B1 (en) | 2001-05-02 | 2006-01-03 | Glaukos Corporation | Implant with pressure sensor for glaucoma treatment |
GR1003802B (en) | 2001-04-17 | 2002-02-08 | Micrel �.�.�. ������� ��������� ��������������� ��������� | Tele-medicine system |
US6706001B2 (en) | 2001-05-11 | 2004-03-16 | Bernard B. Fresco | Dual tonometer pressure measurement device |
JP5079970B2 (en) | 2001-06-29 | 2012-11-21 | エコール ポリテクニーク フェデラル ドゥ ローザンヌ(エーペーエフエル) | Intraocular pressure recording device |
US20030078487A1 (en) | 2001-08-09 | 2003-04-24 | Jeffries Robert E. | Ocular pressure measuring device |
US6712772B2 (en) | 2001-11-29 | 2004-03-30 | Biocontrol Medical Ltd. | Low power consumption implantable pressure sensor |
CA2473355C (en) | 2002-01-18 | 2012-01-03 | Michael E. Snyder | Sustained release ophthalmological device and method of making and using the same |
US7261737B2 (en) | 2002-12-12 | 2007-08-28 | Powervision, Inc. | Accommodating intraocular lens system and method |
US8048155B2 (en) | 2002-02-02 | 2011-11-01 | Powervision, Inc. | Intraocular implant devices |
US6710355B2 (en) | 2002-02-07 | 2004-03-23 | Honeywell International Inc. | Optically powered resonant integrated microstructure pressure sensor |
US20050159660A1 (en) | 2002-05-31 | 2005-07-21 | Valentino Montegrande | Intraocular pressure sensor |
AU2003273544A1 (en) | 2002-05-31 | 2003-12-19 | Kevin Montegrande | Intraocular pressure sensor |
US20070123767A1 (en) | 2002-05-31 | 2007-05-31 | Valentino Montegrande | Intraocular pressure sensor and method of use |
FR2833477B1 (en) | 2002-07-02 | 2004-02-13 | Francois Michel | IMPLANT PSEUDO-ACCOMODATIVE OPTICAL EQUIPMENT FOR PRESBYTIA CORRECTION |
AU2003265380A1 (en) | 2002-08-07 | 2004-02-25 | Cardiomems, Inc. | Implantable wireless sensor for blood pressure measurement within an artery |
WO2004019773A1 (en) | 2002-08-27 | 2004-03-11 | Michigan State University | Implantable microscale pressure sensor system |
US7256695B2 (en) | 2002-09-23 | 2007-08-14 | Microstrain, Inc. | Remotely powered and remotely interrogated wireless digital sensor telemetry system |
US7686762B1 (en) | 2002-10-03 | 2010-03-30 | Integrated Sensing Systems, Inc. | Wireless device and system for monitoring physiologic parameters |
US7131945B2 (en) | 2002-10-16 | 2006-11-07 | California Institute Of Technology | Optically powered and optically data-transmitting wireless intraocular pressure sensor device |
US7037335B2 (en) | 2002-11-19 | 2006-05-02 | Eagle Vision, Inc. | Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma |
EP1589866A2 (en) | 2003-01-09 | 2005-11-02 | The Regents of the University of California | Implantable devices and methods for measuring intraocular, subconjunctival or subdermal pressure and/or analyte concentration |
US8200775B2 (en) | 2005-02-01 | 2012-06-12 | Newsilike Media Group, Inc | Enhanced syndication |
WO2005027998A2 (en) * | 2003-09-16 | 2005-03-31 | Cardiomems, Inc. | Implantable wireless sensor |
DE10353144A1 (en) | 2003-11-14 | 2005-06-02 | Cranium Telemetrics Gmbh | Implant for performing intracorpolar measurements |
ITBO20030732A1 (en) * | 2003-12-03 | 2005-06-04 | Tre Esse Progettazione Biomedica S R L | ANTENNA SYSTEM FOR PLANTABLE ELECTROMEDICAL DEVICES IN THE HUMAN BODY, SUCH AS PACEMAKERS, DEFIBRILLATORS OR OTHERS. |
US20050182312A1 (en) | 2004-02-12 | 2005-08-18 | Medtronic Xomed, Inc. | Contact tonometer using MEMS technology |
US7364564B2 (en) | 2004-03-02 | 2008-04-29 | Becton, Dickinson And Company | Implant having MEMS flow module with movable, flow-controlling baffle |
US7026997B2 (en) | 2004-04-23 | 2006-04-11 | Nokia Corporation | Modified space-filling handset antenna for radio communication |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US7252006B2 (en) | 2004-06-07 | 2007-08-07 | California Institute Of Technology | Implantable mechanical pressure sensor and method of manufacturing the same |
US20060135864A1 (en) | 2004-11-24 | 2006-06-22 | Westerlund L E | Peri-orbital trauma monitor and ocular pressure / peri-orbital edema monitor for non-ophthalmic surgery |
WO2006067638A2 (en) | 2004-12-20 | 2006-06-29 | Amo Groningen B.V. | Amphiphilic block copolymers and their use |
US8029515B2 (en) | 2005-01-31 | 2011-10-04 | Yichieh Shiuey | Corneal implants and methods and systems for placement |
DE102005032989A1 (en) | 2005-07-14 | 2007-01-25 | Imi Intelligent Medical Implants Ag | Extraocular epiretinal implant |
US8088161B2 (en) | 2005-07-28 | 2012-01-03 | Visioncare Ophthalmic Technologies Inc. | Compressed haptics |
US7595723B2 (en) | 2005-11-14 | 2009-09-29 | Edwards Lifesciences Corporation | Wireless communication protocol for a medical sensor system |
US7682313B2 (en) | 2005-11-23 | 2010-03-23 | Vital Sensors Holding Company, Inc. | Implantable pressure monitor |
JP2009519769A (en) | 2005-12-15 | 2009-05-21 | カーディアック ペースメイカーズ, インコーポレイテッド | Method and apparatus for small power supplies for implantable devices |
US20070236213A1 (en) | 2006-03-30 | 2007-10-11 | Paden Bradley E | Telemetry method and apparatus using magnetically-driven mems resonant structure |
EP2786701B1 (en) | 2006-08-29 | 2015-12-23 | California Institute of Technology | Microfabricated implantable wireless pressure sensor for use in biomedical applications and pressure measurement and sensor implantation methods |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US7724148B2 (en) | 2006-11-20 | 2010-05-25 | Radi Medical Systems Ab | Transceiver unit in a pressure measurement system |
US8174395B2 (en) | 2006-11-20 | 2012-05-08 | St. Jude Medical Systems Ab | Transceiver unit in a measurement system |
AR058947A1 (en) | 2007-01-08 | 2008-03-05 | Consejo Nac Invest Cient Tec | IMPLANTABLE MICROAPARATE IN THE EYE TO RELIEF GLAUCOMA OR CAUSING DISEASE OF EYE OVERPRESSION |
US9774086B2 (en) | 2007-03-02 | 2017-09-26 | Qualcomm Incorporated | Wireless power apparatus and methods |
EP2161004B1 (en) | 2007-05-30 | 2017-12-27 | Hoya Corporation | Intraocular lens inserting tool |
US10342701B2 (en) | 2007-08-13 | 2019-07-09 | Johnson & Johnson Surgical Vision, Inc. | Systems and methods for phacoemulsification with vacuum based pumps |
EP2182841A4 (en) | 2007-08-23 | 2013-04-03 | Purdue Research Foundation | Intra-occular pressure sensor |
US7978062B2 (en) | 2007-08-31 | 2011-07-12 | Cardiac Pacemakers, Inc. | Medical data transport over wireless life critical network |
PL2211685T3 (en) | 2007-10-19 | 2017-12-29 | Sensimed Sa | Intraocular pressure monitoring device |
FR2924913B1 (en) | 2007-12-18 | 2010-02-05 | Alain Telandro | SYSTEM FOR MEASURING OCULAR PRESSURE |
KR101634983B1 (en) | 2008-01-07 | 2016-07-01 | 살루타리스 메디컬 디바이스즈, 인코퍼레이티드 | Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye |
US9107592B2 (en) | 2008-03-12 | 2015-08-18 | The Trustees Of The University Of Pennsylvania | Flexible and scalable sensor arrays for recording and modulating physiologic activity |
CN105251007A (en) | 2008-05-09 | 2016-01-20 | 马缇医疗股份有限公司 | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
US8926524B2 (en) | 2008-06-02 | 2015-01-06 | California Institute Of Technology | System, apparatus and method for biomedical wireless pressure sensing |
ES2330405B1 (en) | 2008-06-06 | 2010-09-21 | Consejo Superior De Investigaciones Cientificas (Csic) (45%) | SENSOR CONTACT LENS, SYSTEM FOR NON-INVASIVE MONITORING OF INTRAOCULAR PRESSURE AND METHOD TO PUT YOUR MEASUREMENT. |
DE102008040142A1 (en) | 2008-07-03 | 2010-01-07 | Robert Bosch Gmbh | Capsule clamp with coil for inductive coupling to an external electromagnetic field |
US8264240B2 (en) | 2008-07-20 | 2012-09-11 | Cardiomems, Inc. | Physical property sensor with active electronic circuit and wireless power and data transmission |
US8593107B2 (en) | 2008-10-27 | 2013-11-26 | Cardiac Pacemakers, Inc. | Methods and systems for recharging an implanted device by delivering a section of a charging device adjacent the implanted device within a body |
EP2358305A4 (en) | 2008-11-26 | 2014-02-26 | Anew Optics Inc | Intraocular lens optic |
CA2745638C (en) | 2008-12-02 | 2018-06-26 | Purdue Research Foundation | Radio transparent sensor implant package |
US9662021B2 (en) | 2009-01-12 | 2017-05-30 | Purdue Research Foundation | Miniature stent-based implantable wireless monitoring devices |
PL2391419T3 (en) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8442641B2 (en) | 2010-08-06 | 2013-05-14 | Nano-Retina, Inc. | Retinal prosthesis techniques |
EP2396070A4 (en) | 2009-02-12 | 2012-09-19 | Incept Llc | Drug delivery through hydrogel plugs |
US8182435B2 (en) | 2009-05-04 | 2012-05-22 | Alcon Research, Ltd. | Intraocular pressure sensor |
US8123687B2 (en) | 2009-05-07 | 2012-02-28 | Alcon Research, Ltd. | Intraocular pressure sensor |
WO2010129905A1 (en) | 2009-05-08 | 2010-11-11 | Innolene Llc | Ocular lens |
RU2012102316A (en) * | 2009-07-14 | 2013-08-20 | Эленза, Инк. | FOLDABLE INTRAOCULAR LENSES |
US8361591B2 (en) | 2009-08-12 | 2013-01-29 | Medos International Sarl | Packaging with active protection layer |
US8313819B2 (en) | 2009-08-12 | 2012-11-20 | Medos International S.A.R.L. | Ultra-thin multi-layer packaging |
US8313811B2 (en) | 2009-08-12 | 2012-11-20 | Medos International S.A.R.L. | Plasma enhanced polymer ultra-thin multi-layer packaging |
US7959570B2 (en) | 2009-08-31 | 2011-06-14 | Eniko Todorov Enikov | Eye tonometry apparatus, systems and methods |
IN2012DN03211A (en) | 2009-09-18 | 2015-10-23 | Orthomems Inc | |
WO2011035228A1 (en) * | 2009-09-18 | 2011-03-24 | Orthomems, Inc. | Implantable mems intraocular pressure sensor devices and methods for glaucoma monitoring |
US8257295B2 (en) | 2009-09-21 | 2012-09-04 | Alcon Research, Ltd. | Intraocular pressure sensor with external pressure compensation |
US20110160609A1 (en) | 2009-12-29 | 2011-06-30 | Stone Robert T | Method and system for monitoring pressure in a body cavity |
WO2011082314A2 (en) | 2009-12-30 | 2011-07-07 | Brockman Holdings Llc | System, device, and method for determination of intraocular pressure |
US9968254B2 (en) | 2010-01-05 | 2018-05-15 | Sensimed Sa | Intraocular pressure monitoring device |
JP5856569B2 (en) | 2010-02-05 | 2016-02-10 | サイト サイエンシーズ, インコーポレイテッド | Device for reducing intraocular pressure and kit including the same |
US9320647B2 (en) | 2010-03-31 | 2016-04-26 | Ocuject, Llc | Device and method for intraocular drug delivery |
US20110245753A1 (en) | 2010-04-05 | 2011-10-06 | Sunalp Murad A | Apparatus and method for lowering intraocular pressure in an eye |
RU2013102532A (en) | 2010-06-20 | 2014-07-27 | Эленза, Инк. | OPHTHALMIC DEVICES AND METHODS WITH SPECIALIZED INTEGRAL CIRCUITS |
US9622853B2 (en) | 2010-07-05 | 2017-04-18 | Jagrat Natavar DAVE | Polymeric composition for ocular devices |
DE102010035294A1 (en) | 2010-08-25 | 2011-12-22 | Implandata Ophthalmic Products Gmbh | Sclera sensor |
WO2012031277A1 (en) | 2010-09-02 | 2012-03-08 | Optimedica Corporation | Patient interface for ophthalmologic diagnostic and interventional procedures |
US20120238857A1 (en) | 2010-09-16 | 2012-09-20 | Orthomems, Inc. | Expandable implantable pressure sensor for intraocular surgery |
CN201814556U (en) * | 2010-09-27 | 2011-05-04 | 崔浩 | Pressure-pickup device for intraocular pressure tester |
US8551163B2 (en) | 2010-10-07 | 2013-10-08 | Everheart Systems Inc. | Cardiac support systems and methods for chronic use |
US10842671B2 (en) | 2010-11-15 | 2020-11-24 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
EP2648608A2 (en) | 2010-12-10 | 2013-10-16 | ICPCheck Inc. | Implantable pressure sensor |
US8424388B2 (en) | 2011-01-28 | 2013-04-23 | Medtronic, Inc. | Implantable capacitive pressure sensor apparatus and methods regarding same |
US9427493B2 (en) | 2011-03-07 | 2016-08-30 | The Regents Of The University Of Colorado | Shape memory polymer intraocular lenses |
WO2012134213A2 (en) | 2011-03-31 | 2012-10-04 | 엘지전자 주식회사 | Method for transmitting/receiving message for receiving broadcasting service reception in wireless communication system and apparatus for same |
US8578795B2 (en) | 2011-03-31 | 2013-11-12 | DePuy Synthes Products, LLC | Monitoring and recording implantable silicon active pressure transducer |
EP2517619B1 (en) | 2011-04-27 | 2013-05-22 | Istar Medical | Improvements in or relating to glaucoma management and treatment |
WO2012149278A1 (en) | 2011-04-29 | 2012-11-01 | Allergan, Inc. | Sustained release latanoprost implant |
EP2540261A1 (en) | 2011-06-30 | 2013-01-02 | Sanofi-Aventis Deutschland GmbH | Intraocular medicament delivery device |
WO2013019714A1 (en) | 2011-07-29 | 2013-02-07 | The Trustees Of Columbia University In The City Of New York | Mems affinity sensor for continuous monitoring of analytes |
EP3659495B1 (en) | 2011-09-13 | 2022-12-14 | Dose Medical Corporation | Intraocular physiological sensor |
EP2763581B1 (en) | 2011-10-05 | 2018-01-24 | Sensimed SA | Intraocular pressure measuring and/or monitoring device |
WO2013056130A1 (en) | 2011-10-12 | 2013-04-18 | Purdue Research Foundation | Pressure sensors for small-scale applications and related methods |
KR101308104B1 (en) | 2011-10-24 | 2013-09-12 | 한국과학기술연구원 | Biocompatible pressure sensor and manufacturing method thereof |
US20130110540A1 (en) | 2011-10-26 | 2013-05-02 | Patient Identification Network LLC | Method of Collecting Patient Information in an Electronic System |
US9339187B2 (en) | 2011-12-15 | 2016-05-17 | Alcon Research, Ltd. | External pressure measurement system and method for an intraocular implant |
WO2013090886A1 (en) | 2011-12-16 | 2013-06-20 | California Institute Of Technology | System and method for sensing intraocular pressure |
US9101444B2 (en) | 2012-01-12 | 2015-08-11 | Innfocus, Inc. | Method, surgical kit and device for treating glaucoma |
DE102012200574A1 (en) | 2012-01-17 | 2013-07-18 | Robert Bosch Gmbh | Implant device, sensor module, disposable injector with an implant device and method for producing an implant device |
DE102012100441A1 (en) | 2012-01-19 | 2013-07-25 | Implandata Ophthalmic Products Gmbh | Method and device for the continuous measurement of intraocular pressure |
EP2806828B1 (en) | 2012-01-24 | 2021-07-21 | The Regents of The University of Colorado, A Body Corporate | Modular intraocular lens designs and methods |
JP2013158415A (en) | 2012-02-02 | 2013-08-19 | Omushii:Kk | Blood pressure monitoring system and blood pressure measuring device |
US20130226293A1 (en) | 2012-02-23 | 2013-08-29 | Novartis Ag | Accommodative iol - refractive index change through change in polarizability of a medium |
US9095412B2 (en) | 2012-03-20 | 2015-08-04 | Sight Sciences, Inc. | Ocular delivery systems and methods |
AU2013235467B2 (en) | 2012-03-21 | 2017-11-09 | Alcon Inc. | Intraocular lens delivery systems and methods of use |
JP6465490B2 (en) | 2012-03-26 | 2019-02-06 | グローコス コーポレーション | Implant delivery device |
PL2852318T3 (en) | 2012-05-21 | 2017-07-31 | Sensimed Sa | Intraocular pressure measuring and/or monitoring system with inertial and/or environmental sensor |
US9535264B2 (en) | 2012-07-13 | 2017-01-03 | Adlens Beacon, Inc. | Fluid lenses, lens blanks, and methods of manufacturing the same |
US9307905B2 (en) | 2012-09-14 | 2016-04-12 | University Of Washington | Intraocular pressure sensing devices and associated systems and methods |
US9295389B2 (en) | 2012-12-17 | 2016-03-29 | Novartis Ag | Systems and methods for priming an intraocular pressure sensor in an intraocular implant |
US9022968B2 (en) | 2013-01-08 | 2015-05-05 | University Of South Florida | Auto-regulation system for intraocular pressure |
US8874182B2 (en) | 2013-01-15 | 2014-10-28 | Google Inc. | Encapsulated electronics |
US9730638B2 (en) * | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
KR102322747B1 (en) | 2013-03-15 | 2021-11-08 | 알레간 인코포레이티드 | Prostamide-containing intraocular implant |
EP2976042B1 (en) | 2013-03-21 | 2023-09-13 | Shifamed Holdings, LLC | Accommodating intraocular lens |
US9962084B2 (en) | 2013-06-15 | 2018-05-08 | Purdue Research Foundation | Wireless interstitial fluid pressure sensor |
US9226851B2 (en) * | 2013-08-24 | 2016-01-05 | Novartis Ag | MEMS check valve chip and methods |
US10613356B2 (en) | 2013-09-09 | 2020-04-07 | The General Hospital Corporation | Remotely controllable lens device |
DK3062775T3 (en) | 2013-10-31 | 2018-03-12 | Allergan Inc | PROSTAMID-CONTAINING INTRAOCULAR IMPLANTS AND PROCEDURES FOR USE THEREOF |
ES2754060T3 (en) | 2013-11-19 | 2020-04-15 | Ingeneus Pty Ltd | Device to determine an intraocular pressure of an eye |
US9301082B2 (en) | 2013-12-06 | 2016-03-29 | Apple Inc. | Mobile device sensor data subscribing and sharing |
US9289123B2 (en) | 2013-12-16 | 2016-03-22 | Verily Life Sciences Llc | Contact lens for measuring intraocular pressure |
JP2017504409A (en) | 2014-01-08 | 2017-02-09 | エレンザ, インコーポレイテッド | Electro-optic single focus intraocular lens |
AU2015226833B2 (en) | 2014-03-07 | 2019-11-28 | Lions Eye Institute Limited | Method and system for determining intracranial pressure |
AU2015236131B2 (en) | 2014-03-28 | 2019-05-30 | Forsight Vision6, Inc. | Accommodating intraocular lens |
US10206569B1 (en) | 2014-05-12 | 2019-02-19 | Gholam A. Peyman | Corneal intraocular pressure sensor and a surgical method using the same |
US10044227B2 (en) | 2014-06-02 | 2018-08-07 | Purdue Research Foundation | Magnetic resonance coupling arrangement |
US9690118B2 (en) | 2014-06-13 | 2017-06-27 | Verily Life Sciences Llc | Eye-mountable device to provide automatic accommodation and method of making same |
DE102014212457A1 (en) | 2014-06-27 | 2015-12-31 | Implandata Ophthalmic Products Gmbh | Implant for the determination of intraocular pressure |
JP2017520337A (en) | 2014-07-01 | 2017-07-27 | インジェクトセンス, インコーポレイテッド | Ultra-low power rechargeable implantable sensor with wireless interface for patient monitoring |
JP2017520327A (en) | 2014-07-01 | 2017-07-27 | インジェクトセンス, インコーポレイテッド | Method and device for implanting an intraocular pressure sensor |
PE20151266A1 (en) | 2014-07-01 | 2015-09-10 | Velasquez Mario Eduardo Miranda | DRAINAGE DEVICE FOR THE CONTROL OF INTRAOCULAR PRESSURE IN GLAUCOMA |
EP3182881B1 (en) | 2014-08-20 | 2023-11-29 | California Baptist University | Systems for monitoring eye health |
US10201451B2 (en) | 2014-08-29 | 2019-02-12 | Camras Vision Inc. | Device and method for reducing intraocular pressure |
US9358103B1 (en) | 2015-02-10 | 2016-06-07 | Omega Ophthalmics Llc | Prosthetic capsular devices, systems, and methods |
EP3795125A1 (en) | 2015-03-03 | 2021-03-24 | Electronic Systems S.p.A. | Surgical assembly for ocular surgery, system of compensation of intraocular pressure |
EP3277220A4 (en) | 2015-04-03 | 2018-12-19 | The Regents of the University of Colorado, a body corporate | Devices and methods for stabilization of an ocular lens capsule and preventing artificial intraocular lens implant rotation post cataract surgery |
WO2016210279A1 (en) | 2015-06-26 | 2016-12-29 | Innfocus, Inc. | Glaucoma device delivery system and trans-conjunctival method of delivery |
US11058574B2 (en) | 2015-07-03 | 2021-07-13 | Ophthorobotics Ag | Intraocular injection system and methods for controlling such a system |
WO2017015675A1 (en) | 2015-07-23 | 2017-01-26 | Envisia Therapeutics, Inc. | Glaucoma treatment via intracameral ocular implants |
US10307246B2 (en) | 2015-07-23 | 2019-06-04 | Elwha Llc | Intraocular lens devices, systems, and related methods |
US10449085B2 (en) | 2015-08-19 | 2019-10-22 | Suzanne Paulson | System for treatment of eye conditions |
EP3340949A2 (en) | 2015-08-27 | 2018-07-04 | Equinox, LLC | Eye-related intrabody pressure identification and modification |
JP6643602B2 (en) | 2015-09-07 | 2020-02-12 | 株式会社トーメーコーポレーション | Ophthalmic equipment |
US9985334B2 (en) | 2015-10-21 | 2018-05-29 | Johnson & Johnson Vision Care, Inc. | Antenna mandrel with multiple antennas |
WO2017095825A1 (en) | 2015-11-30 | 2017-06-08 | California Institute Of Technology | System and method for measuring intraocular pressure |
US10722347B2 (en) | 2015-12-17 | 2020-07-28 | Atrion Medical Products, Inc. | Intraocular lens delivery device and method of use |
US20170209045A1 (en) | 2016-01-26 | 2017-07-27 | California Institute Of Technology | System and method for intraocular pressure sensing |
US10383769B1 (en) | 2016-03-30 | 2019-08-20 | Juanita Miller | Eye cover with audio transmitter |
EP3458002A1 (en) | 2016-05-17 | 2019-03-27 | Novartis AG | Automated viscous fluid control in vitreoretinal surgery |
EP3245988B1 (en) | 2016-05-18 | 2023-12-27 | Sonikure Holdings Limited | System for ultrasound-enhanced transscleral delivery of drugs |
CN109157190B (en) | 2016-05-27 | 2019-10-01 | 深圳硅基传感科技有限公司 | Implanted intraocular pressure monitor with protrusion |
EP3669836B1 (en) | 2016-06-03 | 2021-08-04 | New World Medical, Inc. | Intraocular drainage device |
US9993336B2 (en) | 2016-06-06 | 2018-06-12 | Omega Ophthalmics Llc | Prosthetic capsular devices, systems, and methods |
US10285590B2 (en) | 2016-06-14 | 2019-05-14 | The Regents Of The University Of Michigan | Intraocular pressure sensor with improved voltage reference circuit |
EP3474943A4 (en) | 2016-06-22 | 2019-11-13 | Purdue Research Foundation | Wireless glaucoma therapy |
WO2018031982A1 (en) | 2016-08-12 | 2018-02-15 | Alex Artsyukhovich | A surgical laser capsulorhexis system and patient interface lens accessory |
MX2019004237A (en) | 2016-10-12 | 2019-09-18 | Thyzel Reinhardt | Method for changing the perceptual color appearance of the iris of a human's or animal's eye. |
CA3109979C (en) | 2016-10-21 | 2023-10-17 | Omega Ophthalmics Llc | Prosthetic capsular devices |
DE102016221371A1 (en) | 2016-10-28 | 2018-05-03 | Implandata Ophthalmic Products Gmbh | ring implant |
US11684703B2 (en) | 2018-02-20 | 2023-06-27 | Qura, Inc. | Coatings for implantable devices |
US11191962B2 (en) | 2018-03-12 | 2021-12-07 | Purdue Research Foundation | Stimulus coil and pulse generator for wireless glaucoma therapy |
US11602427B2 (en) | 2018-03-30 | 2023-03-14 | Qura, Inc. | Intraocular lenses including an intraocular pressure sensor |
WO2019216945A1 (en) | 2018-05-07 | 2019-11-14 | Qura, Inc. | Business methods based on providing monitoring services and access to information to caregivers, patients with implanted pressure sensors and distributors |
WO2020023036A1 (en) | 2018-07-25 | 2020-01-30 | Qura, Inc. | Implantable intraocular pressure sensors configured as capsular tension rings |
US11806278B2 (en) | 2018-08-30 | 2023-11-07 | Qura, Inc. | Implantable intraocular drug delivery devices |
US20210137379A1 (en) | 2018-10-17 | 2021-05-13 | Jean-Noel Fehr | Intraocular lenses with embedded intraocular pressure sensors |
WO2020081072A1 (en) | 2018-10-17 | 2020-04-23 | Qura, Inc. | Intraocular lenses with embedded intraocular pressure sensors |
WO2020160262A1 (en) | 2019-01-30 | 2020-08-06 | Qura, Inc. | Implantable intraocular pressure sensors and calibration |
WO2020236139A1 (en) | 2019-05-17 | 2020-11-26 | Qura, Inc. | Intraocular lenses with intraocular pressure sensors and methods of manufacture |
-
2017
- 2017-05-31 WO PCT/US2017/035247 patent/WO2017210316A1/en unknown
- 2017-05-31 CN CN202210167305.6A patent/CN114532976A/en active Pending
- 2017-05-31 US US16/302,750 patent/US11497399B2/en active Active
- 2017-05-31 EP EP17807410.0A patent/EP3463044A4/en active Pending
- 2017-05-31 CA CA3024891A patent/CA3024891A1/en active Pending
- 2017-05-31 CN CN201780046657.3A patent/CN109561822B/en active Active
- 2017-05-31 JP JP2018563564A patent/JP2019518546A/en active Pending
-
2022
- 2022-09-30 US US17/937,062 patent/US20230024683A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114532976A (en) | 2022-05-27 |
CN109561822A (en) | 2019-04-02 |
WO2017210316A1 (en) | 2017-12-07 |
CA3024891A1 (en) | 2017-12-07 |
US20190175015A1 (en) | 2019-06-13 |
US11497399B2 (en) | 2022-11-15 |
CN109561822B (en) | 2022-03-04 |
JP2019518546A (en) | 2019-07-04 |
EP3463044A4 (en) | 2020-07-29 |
EP3463044A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230024683A1 (en) | Implantable intraocular pressure sensors and methods of use | |
US20220054007A1 (en) | Implantable intraocular pressure sensors and calibration | |
EP3621512B1 (en) | Implantable extracompartmental pressure sensor | |
JP7254134B2 (en) | Intraocular physiological sensor | |
US11684703B2 (en) | Coatings for implantable devices | |
EP2427098B1 (en) | Intraocular pressure sensor | |
US8182435B2 (en) | Intraocular pressure sensor | |
US8926510B2 (en) | Device and method for glaucoma management and treatment | |
US7131945B2 (en) | Optically powered and optically data-transmitting wireless intraocular pressure sensor device | |
US20160058324A1 (en) | Ultra low power charging implant sensors with wireless interface for patient monitoring | |
US20120238857A1 (en) | Expandable implantable pressure sensor for intraocular surgery | |
CN102497843A (en) | Power saving glaucoma drainage device | |
BR102014029022A2 (en) | ophthalmic lens with intraocular monitoring system | |
CN111388189A (en) | Drainage device for reducing intraocular pressure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: QURA, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ADAMS, DOUGLAS P.;TELLO, CELSO;ACKERMAN, MARCEL DAVID;AND OTHERS;SIGNING DATES FROM 20181029 TO 20181114;REEL/FRAME:061344/0202 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |